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ABSTRACT 
 
CONTRIBUTION OF TOLL-LIKE RECEPTORS TO MESENCHYMAL 
STEM CELL DIFFERENTIATION AND IMMUNOMODULATION 
 
İBRAHİM FIRAT TAŞ 
M.Sc. in Molecular Biology and Genetics 
Supervisors: Assoc. Prof. Dr. İhsan Gürsel & Assoc. Prof. Dr. K. Can Akçalı 
August 2010, 96 Pages  
 
Mesenchymal stem cells (MSC) are pluripotent progenitor cells harboring 
unique characteristics along with several stem cell features such as lineage 
dependent differentiation and self-renewal capacity. MSCs are known to induce 
immunomodulatory activity and homing capacity to damaged tissue sites. Such 
diverse capabilities of MSCs make them distinct from adult stem cells and can be 
harnessed in several therapeutic applications.  
Toll-like receptors (TLR) can recognize conserved microbial byproducts and 
are mainly expressed by innate immune system cells as well as epithelial or 
endothelial cells. Recent findings suggest that in vitro generated MSCs express some 
of these pathogen recognition receptors. In our view, to broaden the breath of the 
therapeutic potential, TLR mediated activation of MSCs and demonstrate its impact 
on differentiation and immunomodulatory activity is critical.  
First, bone marrow-derived MSCs were generated and characterized via their 
surface marker expression by FACS (CD90, CD106 and CD45) at protein level and 
their message transcripts by RT-PCR (CD11b, CD29, CD34, CD45, CD71, CD73, 
CD90 and CD166). The most abundant marker was found to be CD90 over several 
passages. Following determination of TLR expression profile by RT-PCR, 
contribution of TLR ligands addition (TLR2, TLR3, TLR7 and TLR9) to MSCs 
during adipogenic or osteogenic differentiation was studied. TLR3 was found to be 
the most abundant type over several passages. The adipogenic differentiation of 
rMSCs was found to be facilitated in the presence of TLR2 TLR3 and TLR7 ligands. 
Additionally, changes in the adipogenic and osteogenic markers (LPL, PPAR-g for 
adipogenesis, and ALP, OC-1, RUNX for osteogenesis) were analyzed by RT-PCR. 
While adipogenic markers upregulated osteogenic markers were downregulated in 
response to TLR ligand treatment.  
The final part of this study was performed with mouse mesenchymal stem 
cells. In order to define the immunostimulatory/immunosuppressive potential of 
mouse MSCs, immunomodulatory character of MSCs were examined in the presence 
or absence of mouse spleen cells. Our data suggested that when mMSCs are primed 
with TLRL, a pro-inflammatory cascade as evidenced by increased IL-6 and IFN-γ 
secretion is initiated either alone or in co-culture with splenocytes.   
In conclusion, TLR priming of MSCs augments their differentiation primarily 
into adipogenesis, and mainly these cells are immunostimulatory.   
 
Keywords: Mesenchymal stem cells, Toll-like receptors, differentiation, 
immunomodulation. 
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ÖZET 
 
TOLL BENZERİ RESEPTÖRLERİN MEZENKİMAL KÖK HÜCRE 
FARKLILAŞMASINA VE İMMÜNMODÜLASYONUNA KATKILARI 
 
İBRAHİM FIRAT TAŞ 
Moleküler Biyoloji ve Genetik Yüksek Lisans  
Danışmanlar: Doç. Dr. İhsan Gürsel & Doç Dr. K. Can Akçalı 
Ağustos 2010, 96 Sayfa  
 
 Mezenkimal kök hücreler (MKH) değişik doku tiplerine ait hücrelere 
farklılaşabilen ve kendini yenileme gibi çeşitli kök hücre özelliklerinin yanı sıra 
özgün karakteristiklere sahip çok potansiyelli öncül hücrelerdir. MKH, immün 
düzenleyici aktiviteyi uyarma ve yaralı dokuya göç etme özellikleri ile bilinmektedir. 
Bu tür farklı kapasiteleri, MKH’yi, diğer yetişkin kök hücrelerden farklı kılmakta ve 
terapötik uygulamalarda kullanılabilinir hale getirmektedir.    
 Toll-benzeri reseptörler (TBR), korunmuş mikrobiyal yan ürünleri tanımakta 
ve başlıca doğal bağışıklık sistemi hücreleri yanı sıra endotel veya epitel hücreleri 
tarafından da ifade edilmektedirler. Son bulgular, in vitro ortamda geliştirilen 
MKH’nin bu patojen tanıyıcı reseptörlerden bazılarını ifade ettiğini ileri sürmektedir. 
Görüşümüze göre, terapötik uygulamalarını genişletmek için TLR aracılıklı MKH 
aktivasyonu ile bu durumun hücre farklılaşma ve immün düzenleyici potansiyeli 
üzerine olan etkilerini araştırmak kritiktir.  
 İlk olarak, kemik iliği kökenli MKH geliştirildi ve yüzey işaretçilerinin 
ifadesi (CD45, CD90 ve CD106) FACS ile protein seviyesinde; mesaj transkriptleri 
(CD11b, CD34, CD45, CD71, CD73, CD90 ve CD166) RT-PCR ile karakterize 
edilmiştir. Hücre pasajları boyunca CD90 en bol işaretçi olarak bulunmuştur. TBR 
ifade profillerinin RT-PCR ile belirlenmesinden sonra; 
TBR ulaklarının (TBR2, 3, 7 ve 9) MKH’nin adipojenik ve osteojenik 
farklılaşmasına katkısı çalışılmıştır. Farklı hücre pasajlarında TBR3 en yoğun 
bulunan tip olarak bulunmuştur. Sıçan MKH’lerin adipojenik farklılaşmasının TBR2, 
TBR3 ve TBR7 ulaklarının varlığında hızlandığı bulunmuştur. Ayrıca, adipojenik ve 
osteojenik değişimlere özgün işaretçilerin (adipojenez için LPL, PPAR-g ile 
osteojenez için ALP, OC–1 ve RUNX) mesaj düzeyleri RT-PCR ile analiz edilmiştir. 
TBR ulaklarının muamelesine karşılık olarak adipojenik işaretçilerin ifadesi artarken 
osteojenik işaretçilerin ifadesi azalmıştır.   
 Bu çalışmanın son kısmı fare MKH’leri ile gerçekleştirilmiştir. Fare 
MKH’sinin immün uyarıcı/baskılayıcı potansiyelini belirlemek için fare MKH’sinin 
immün düzenleyici karakteri fare dalak hücreleri varlığında ve yokluğunda 
araştırılmıştır. Verilerimiz,  fare MKH’sinin TBR işlemesiyle, yalnız olarak veya 
dalak hücreleriyle ko-kültür ortamında, IL-6 ve IFN-γ salınımının tanıklığında pro-
inflamatuvar bir akışın başlatıldığını önermektedir. 
 Sonuç olarak, MKH’nin TBR işlemesi öncelikle adipojenez olmak üzere 
hücrelerin farklılaşmasını artırmaktadır ve temelde bu hücreler immün uyarıcıdır.  
 
 
Anahtar kelimeler: Mezenkimal kök hücre, Toll-benzeri reseptör, farklılaşma, 
immün modülasyon 
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1. INTRODUCTION 
 
1.1. Mesenchymal Stem Cells 
 
The history of mesenchymal stem cells (MSCs) can go back to mid 60’s. The first 
efforts for describing a stem cell population in bone marrow brought to attention 
after observation of osteogenic differentiation of fully and partially transplanted bone 
marrow into mice (Friedenstein et al., 1966). The discovery of MSCs was done by 
Friedenstein and colleagues in 1966. However, at that time it was not possible to 
fully describe this cell type. Later intensive studies revealed that there is a fibroblast-
like cell population in bone marrow able to form colonies in culture (Friedenstein et 
al., 1970). As the studies concentrated on establishing the possible cell population 
present in bone marrow with osteogenic differentiation capacity, information on the 
MSCs has continued to accumulate up to now. Despite all the studies performed 
about MSC biology, several issues are still unresolved and inconsistencies present in 
the literature.   
 
1.1.1. Characterization of Mesenchymal Stem Cells 
 
For any given cell type, characterization of that particular cell is an essential and first 
step for studying this cell population. In MSC case, unfortunately due to variations in 
common practice while culturing BM cells to yield MSC common “gold standard” 
markers are not available. Today, with every paper published, there is a different 
statement claimed for MSC characterization. These discrepancies preclude an 
acceptable consensus on the establishment of standard method for MSC 
characterization. Among many, one approach used in common to characterize MSC 
generation is to demonstrate their capacity to differentiate tissue-specific cells. MSCs 
are now accepted as multipotent cell populations that can differentiate into three 
main mesenchymal lineages; adipocytes, osteocytes and chondrocytes (Pittenger et 
al., 1999). With their unique multipotential ability, at least these stem cells are 
distinguished from other stem cell types co-existing in the bone marrow niche. 
However, one method would not be sufficient to fully annotate a cell as MSC. Other 
methods applied to characterize is the surface marker expression profiles. Since there 
are controversial views about rate and type and level of expression of certain genes 
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as markers of MSCs among the species, still a handful of CD markers do present on 
MSCs regardless of the type of the host. These are CD90, CD73, CD105 according 
to International Society for Cellular Therapy, ISCT (Dominici et al., 2006). In 
addition to these positive markers, CD11b, CD34, CD45 or CD14 and HLA-DR 
surface molecules were regarded as negative markers of MSCs. The third and the 
most convenient method is the plastic adherence property of these cells. This method 
is a “gold standard” nearly for 40 years beginning with the first identification of 
MSCs (Friedenstein et al., 1966). Since, hematopoietic stem cells and erythrocytes 
do not attach to plastic surfaces; MSCs can be easily isolated from the rest of the 
cells with this primitive feature during bone marrow culturing. Today, these three 
main methods are widely used and accepted for MSC isolation and characterization. 
Nevertheless, the scientists are still investing considerable effort in order to describe 
more common, universally acceptable MSC markers.  
 
1.1.2. The Mesenchymal Stem Cell Niches in Body 
 
The main and the most abundant niche of MSC is bone marrow. Besides MSCs, bone 
marrow consists of a variety of other cell types including progenitors for blood cells, 
and other stromal cells (Dorshkind, 1990). Within this microenvironment, MSCs 
makes up the 0.001%-0.01% of the whole cell population. This ratio was determined 
with Percoll density gradient centrifugation (Pittenger et al., 1999). The efforts for 
isolation of MSCs from tissues other than bone marrow are due to the need for 
finding better non-invasive sites. In the search for such an alternative source of MSC, 
there are a number of other tissues/sites where MSCs were successfully isolated. 
These include but not limited to umbilical cord blood (Romanov et al., 2003), 
adipose tissues (da Silva Meirelles et al., 2009; De Ugarte et al., 2003; Nathan et al., 
2003) and umbilical cord matrix (Zeddou et al., 2010).  In addition to these tissues, 
trabecular bone (Noth et al., 2002), synovium (Fickert et al., 2003), vascular wall 
(Abedin et al., 2004) and periosteum (Nathan et al., 2003) are found to be consisting 
MSCs in adults. What’s more, during development processes, MSCs were also 
isolated from liver (Anker et al., 2003; Paniushina et al., 2004), heart (Warejcka et al., 
1996), spleen and lung (Anker et al., 2003), derma (Chunmeng and Tianmin, 2004) 
and pancreas (Hu et al., 2003).   
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1.1.3. Differentiation Capacity of Mesenchymal Stem Cells 
 
The first defined potential of MSC was in the direction of differentiation into 
osteocytes (Friedenstein et al., 1966). Within years, standardization was brought for 
characterization of MSCs in terms of differentiation capacity. Recently, MSCs are 
accepted as having capacity to differentiate at least into three lineages; adipocytes, 
osteocytes and chondrocytes (Pittenger et al., 1999). However, studies revealed that 
MSCs have much more capacity than previously stated. For instance, these stem cells 
have potential to develop into ligaments and tendons when embedded in collagen and 
subjected to mechanical force (Altman et al., 2002). MSCs were also reported to 
differentiate into endotheliocytes both in vitro (Campioni et al., 2003) and in vivo 
(Silva et al., 2005). In addition to these observations, it is also reported that these 
stem cells could be differentiated into cardiomyocytes (Xu et al., 2004). It is 
expectable that MSCs could differentiate into cells of mesenchyme origin. However, 
there are studies also illuminating that MSCs have capacity to differentiate into cells 
of endodermal and ectodermal lineages such as neuron-like cells (Hermann et al., 
2004) and hepatocytes (Wang et al., 2004).  The most widely studied differentiation 
processes of MSCs would be investigated in Figure 1.1. 
 
Figure 1.1 - Multipotency of MSC and differentiation pathways (Adopted from Caplan and Bruder, 
2001 with permission) 
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1.1.4. Immunomodulatory Effects of Mesenchymal Stem Cells 
 
For the characterization of mesenchymal stem cells, functional studies were carried 
out with these cells both in vitro and in vivo. During animal studies, MSCs were 
discovered to be suppressing immune system. Further studies demonstrated that these 
cells have immunosuppressive capacity. Moreover, these cells were observed to 
escape from immune system resulting in no immune response even interspecies 
engraftment of these cells (Nauta and Fibbe, 2007; Rasmusson, 2006). The 
immunosuppressive property of these cells was related to the expressed receptors and 
ligands for specific receptors. MSCs express growth factor receptors like TGF-β and 
Wnt (Mishra et al., 2005), adhesion proteins like vascular cell adhesion molecule 
(VCAM), intracellular adhesion molecule (ICAM) and CD166 (Ruster et al., 2006), 
several cytokine and chemokine receptors such as IL-6R, IFN-γR, TNF-α1R, 
CXCR4R, CXCR9 (Honczarenko et al., 2006; Ji et al., 2004), toll-like receptors like 
TLR2 (Pevsner-Fischer et al., 2007), TLR3 and TLR4 (Liotta et al., 2008) and also 
these cells can secrete ligands for natural killer cell receptors (Spaggiari et al., 2006). 
A comprehensive view of immunosuppresion and how it is directed by MSCs for 
several immune cells is summarized in Figure 1.2 (Rasmusson, 2006).  
 
Figure 1.2 - Immunomodulatory effects of MSCs on immune system cells (Adopted from Rasmusson, 
2006 with permission) 
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Especially, immunosuppresion is mediated via these singular interactions. At this 
point, interactions of MSCs with specific immune cells play the key role for 
inhibiting the stimulatory effects of immune system. Since MSCs show the 
expression of several receptors and ligands, it is inevitable that these cells are 
interacting with other cells individually. As a specific point for immunosuppresion, 
MSCs can inhibit the T lymphocytes. The inhibitory action is delivered by 
hampering the maturation of T lymphocytes via a soluble factor, indoleamine 2, 3-
dioxygenase (IDO), which converts the tryptophan required for T lymphocyte 
maturation into kynurenine (Meisel et al., 2004). As in the suppression of T 
lymphocytes, other immune system cells are controlled by MSC with a different 
mechanism or a similar one with T lymphocyte case.  
 
1.1.5. Potential subpopulations of Mesenchymal Stem Cells 
 
It is a well-known fact that bone marrow microenvironment consists of various cell 
types forming a heterogeneous residing place for many cell populations. Considering 
this heterogeneous environment, without no doubt, any cell population removed from 
this tissue would be “contaminated” with neighboring cell types. To get a more 
homogeneous cell group, special isolation processes are performed following the 
bone marrow extraction. However, such isolation procedures would not be sufficient 
to obtain a pure cell population. Recent studies demonstrated that even at the end of 
14 day isolation procedure, mesenchymal stem cells do not display a homogeneous 
cell population (Harting et al., 2008). Moreover, stimulation of these cells with 
different ligands gives different cell profiles (Waterman et al., 2010). It is even 
possible to classify two distinct populations of MSCs according to immuno-
phenotyping (Battula et al., 2009; Buhring et al., 2009). What is more important is, 
these two studies revealed that subpopulations have very different characteristics in 
terms of immunosuppresion. The former study has clearly stated that upon priming 
with different TLR ligands, MSCs were directed into two distinct phenotypes: an 
immunosuppressive and other pro-inflammatory phenotype (Battula et al., 2009). 
Such a pro-inflammatory MSC phenotype was reported previously with IFN-γ 
priming studies of MSCs (Chan et al., 2006; Romieu-Mourez et al., 2009; Stagg et al., 
2006). These and other studies establish the immune plasticity concept for MSCs. 
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Recent reports also stated the presence of a subpopulation defined by high osteogenic 
properties (Leonardi et al., 2009; Liu et al., 2009; Tormin et al., 2009).  
 
1.1.6. Clinical Applications of Mesenchymal Stem Cells 
 
As stated in previous sections, the versatile potentials of MSCs in terms of 
differentiation and migration capacity to the injury site make these cells a valuable 
tool for regenerative medicine and delivery vehicle. The idea of using MSCs in the 
regenerative medicine developed with the discovery of multilineage differentiation 
potential of these cells. These cells were administered following hematopoietic stem 
cell (HSC) transplantation in order to enhance the engraftment of HSCs in patients 
who has hematological disorders (Koc et al., 2000; Lazarus et al., 2005). In addition 
to such benefits of MSCs, these cells are used in tissue repair with patients suffering 
bone and cartilage disorders (Horwitz et al., 2002; Horwitz et al., 1999; Turgeman et 
al., 2002). In addition to these applications, MSCs were also administered to patients 
who had myocardial infarction and significant improvements with the heart function 
were recorded (Stamm et al., 2003). Beside such studies, MSCs were also used for 
their immunosuppressive properties. In order to prevent the engrafted tissue rejection, 
MSCs were also administered along with or following the tissue transplantation. 
Such studies demonstrated that graft-versus-host disease (GvHD) which results 
following tissue transplantation was prevented via immunosuppressive feature of 
MSCs. (Le Blanc et al., 2008; Le Blanc et al., 2004). Additionally, MSCs were 
benefited as a delivery vehicle to desired tissue using their migration capacity. Such 
studies generally include the cancer therapy and in these studies MSCs were loaded 
with anti-cancer drugs (Nakamizo et al., 2005; Studeny et al., 2004).  
 
1.2. Mesenchymal Stem Cells and Toll-Like Receptors 
 
Recently, therapeutic applications of mesenchymal stem cells had a broad range in 
different disease states. These applications do not include only regenerative medicine 
but also in cancer therapy. MSCs provide a safe biological delivery tool. However, 
these stem cells have some unique properties that put them in a different position 
than only being multipotent stem cell. These cells express several cytokine 
(Honczarenko et al., 2006; Ji et al., 2004) and other immune system receptors, 
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especially TLRs (Pevsner-Fischer et al., 2007). What’s more, MSCs can behave 
differently under unfavorable conditions such as hypoxia (Cho et al., 2006) and 
inflammation (Raicevic et al., 2010). Defining the behavioral changes in MSCs 
under these conditions carries significant information in terms of suitable and reliable 
administration of these cells.  
 
In the recent years, it is proposed that, TLRs can mediate the immunomodulatory 
potential of MSCs, yet there are several unresolved and contradicting issues on this 
topic. These modulations are in the way of stimulating down-stream signaling of 
TLRs and thus providing MSCs a more immunostimulatory character (Romieu-
Mourez et al., 2009). Additionally, stimulation of TLR with the proper ligands 
causes an increase in the migratory capacity of MSCs (Tomchuck et al., 2008). 
Moreover, some studies have shown that TLR ligand priming had resulted in changes 
with the differentiation capacity of MSCs. For instance, MSCs stimulated with TLR3 
and TLR4 ligands had an increased osteogenic differentiation capacity (Lombardo et 
al., 2009). Parallel to the stated effects of TLR3 and TLR4, these receptors have been 
shown to inhibit the modulatory activity of T lymphocytes by means of hampering 
Notch signaling (Liotta et al., 2008). Along with these studies, in a recent study it is 
stated that lipopolysaccharide which is a ligand for TLR4 had increased the 
proliferation rate of MSCs (Wang et al., 2009). Like in the characterization problem 
of MSCs, today there are a number of papers stating inconsistent results in similar 
experimental systems. Such controversial findings raise a new concept about MSCs. 
Do they possess opposing suppopulations? A recent paper claimed that stimulation 
with two different TLR ligands has resulted two converse MSC types (Waterman et 
al., 2010). Without doubt, in the near future there will be more findings supporting 
this view of differential contribution of TLR engagement and its involvement on 
MSC immunobiology.  
 
1.3. The Immune System 
 
The main goal of immune system of an organism is to distinguish the foreign 
particles from the self-particles. This “self vs non-self” distinguishment of immune 
system is the first strategy in the way of protection mechanism. It is crucial to 
perform this distinguishment properly. For a proper distinguishment, the immune 
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system is “trained” from the first development stages of an organism. For instance, 
human immune system is “educated” in the womb against the foreign particles, 
antigens, of mother. Any mistake made in the defining of self and non-self antigens 
would result in problems with the immune system like autoimmune diseases, chronic 
diseases or even with death. Thus, this process has a pivotal importance in the 
immune system. In addition to “training” process of immune system, this system has 
also other strategies to recognize foreign particles. The immune system can be 
categorized into two different subtypes; innate and acquired (adaptive) immune 
system. The innate immune system has evolutionarily conserved universal 
mechanisms to recognize foreign particles whereas adaptive immune system has 
unique property to “learn” and “remember” previously encountered antigens with 
specificity (Akira et al., 2001). Beside adaptation and memory of adaptive immune 
system has also some disadvantages like allergy and rejection of tissues following 
transplantation (Medzhitov and Janeway, 1998).  
 
1.3.1. The Innate Immune System 
 
The innate immune system has been universally found in a very wide range of 
organisms from different levels. The innate system is composed of mucosal epithelia, 
being the first line of host defense, and several cell types, like natural killer cells, 
phagocytes, expressing similar receptor profiles. Since the innate system is an 
ancient way of pathogen recognition, this system has limited germline-encoded 
receptors in number. Corresponding with the receptor limitation, this system has such 
a limit in the particle recognition. Only the universally conserved structures are 
recognized by this system (Janeway and Medzhitov, 2002). Conversely to this 
system, adaptive immune system has an unlimited antigen recognition system. 
However, without the innate immune system, the adaptive immune system cannot 
provide the protection against foreign particles since these two systems function in 
harmony. Actually, the innate immune system takes part in the first branch of 
recognition and with the response given by innate immune system, adaptive immune 
system settles a more vigorous further response (Medzhitov et al., 1997). Such 
situations take place when the innate immune system is unable to challenge the 
pathogen or recognize the pathogen. At this point, adaptive immune system gets into 
action and “generate” receptors for the recognition of pathogen. These receptors are 
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expressed with the somatic recombination of the gene segments which provides a 
variety of receptor types (Schatz et al., 1992). However, the innate immune system, 
as previously mentioned, has a limited number of receptors for fighting off the 
pathogens. These receptors are called pattern recognition receptors (PRRs) and 
recognize the pathogen associated molecular patterns (PAMPs) (Akira et al., 2006).  
 
1.3.1.1. Pattern Recognition Receptors 
 
These receptors are found on innate immune system cells and implement their 
functions through recognizing the non-self pathogen-associated molecular structures 
that build up the main structures of microorganisms. These receptors are germ-line 
encoded meaning that in any given cell type of innate immune system, all cells 
express these receptors. Contrary to adaptive immune cells, T and B-lymphocytes, 
the cells expressing these receptors do not have immunological memory or 
specificity. What’s more, each PRR can recognize a specific PAMP regardless of the 
development stage of related microorganism (Akira et al., 2006). PRRs have distinct 
mechanisms of serving their functions. The most prevalent one is the activation of 
proinflammatory signaling pathways. Again the widely activated proinflammatory 
pathway is the nuclear factor-kappa B (NF-κB) pathway and to a lesser extent 
mitogen activated protein (MAP) kinase pathway (Clemens and Elia, 1997). Other 
mechanisms include the induction of apoptosis, phagocytosis and opsonization.  
 
There are three main classes of PRRs: nucleotide binding oligomerization domain 
(NOD)-like receptors (NLRs), retinoic acid-inducible gene I (RIG)-like helicases 
(RLHs) and Toll-like receptors  (TLRs) (Kawai and Akira, 2006).  
 
1.3.1.1.1. Toll-Like Receptors as Pattern Recognition Receptors  
 
The Toll-like receptor name was given after the discovery of a homologue Toll 
protein in human that was first defined in Drosophila melanogaster. Just like the 
function in D. melanogaster, human homologue of Toll protein was inducing the 
innate immune system through the NF-κB signaling pathway as well. By cloning and 
characterization studies, TLRs were defined as type I transmembrane receptors with 
leucine-rich repeats (LRR) containing extracellular domains and an intracellular 
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Toll/IL-1 receptor (TIR) homology domain (Medzhitov et al., 1997). As TLRs are 
found to be a part of innate immune system, they were also characterized with the 
evolutionary conservation from Caenorhabditis elegans to higher vertebrates, 
humans (Roach et al., 2005). From the identification of TLRs for the first time, up to 
now, 10 TLRs in humans and 13 in murines have been identified. There are a number 
of differences among the TLRs such as ligand specificities, expression profiles, 
target genes that are induced by these receptors and the signaling pathways as well 
(Kumagai et al., 2008).   
 
1.3.1.1.2. Toll-Like Receptors in Innate and Adaptive Immunity 
 
Defined as one of the main functioning units for innate immune system, TLRs are 
expressed on a variety of innate immune system cells such as dendritic cells and 
macrophages. Although, TLRs are characterized as PRRs of innate immune system 
cells, these receptors are also expressed on B cells and some specific types of T cells 
from adaptive immune system. Moreover, the expression profiles of these receptors 
can include the fibroblasts and epithelial cells (Kumagai et al., 2008). Interestingly 
stem cells are also found to be expressing these receptors (Pevsner-Fischer et al., 
2007; Scumpia et al., 2010). Besides their wide expression range, these receptors are 
also found to be taking role in directing the innate immune system response and 
linking innate immune responses with adaptive immune system (Majewska and 
Szczepanik, 2006; Takeda et al., 2003). Most of the time, flow of information from 
innate immunity to adaptive immunity is provided by dendritic cells. Recognition of 
pathogens by DCs via TLRs causes the expression of co-stimulatory molecules, like 
CD80/CD86. This induction is crucial for activation and survival of T cells. Along 
with this action, pathogen recognition by DCs ends up in the induction of 
inflammatory signals and as a result of this induction, inflammatory cytokines are 
produced (Akira et al., 2001).  
 
1.3.1.1.2.1. The Toll-Like Receptor Family Members 
 
In mammals, 10 members of TLRs are identified up to now (Rakoff-Nahoum and 
Medzhitov, 2009) and in mice 13 TLRs are identified (Takeda and Akira, 2007). 
Among these TLRs, the first characterized one was the human TLR4 (Poltorak et al., 
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1998). Within such diverse TLR member family, it is possible to classify these 
receptors according to different properties possessing. However, the localization of 
these receptors in a cell supplies the most convenient way of categorizing. Thus, 
TLR1, 2, 4, 5, 6 and 11 make a TLR subtype located on the cell membrane while 
TLR3, 7, 8 and 9 forms another subtype existing in the intracellular endosomal 
and/or endoplasmic reticulum parts (Iwasaki and Medzhitov, 2004). Moreover, the 
former subtype presumably specialized in the recognition of main bacterial structures 
whereas the latter subtype recognizes the viral and bacterial nucleic acids specific to 
these microorganisms (Rakoff-Nahoum and Medzhitov, 2009) (Figure 1.3). 
 
 
Figure 1.3 - Localizations of Toll-like receptors and related ligands for each TLR (Adopted from 
Rakoff-Nahoum and Medzhitov, 2009 with permission). 
  
As depicted in the Figure 1.3, TLRs can function alone or in dimers with another 
TLR or self. The dimerization is necessary for the induction of proper signaling 
pathways. Another reason for dimerization is to recognize specific pathogen particles, 
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which will be explained in detail in each TLR section. For such a recognizing pattern, 
TLR2 forms heterodimer with TLR1 and TLR6. That’s why, these three TLRs will 
be investigated under one topic. 
 
1.3.1.1.2.1.1. TLR1,2 and 6 
 
TLR2 is the most extensively studied among these three TLRs. Since TLR2 is known 
to recognize a wide range of microbial particles such as peptidoglycan (PGN) and  
lipoteichoic acid (LTA) from Gram-positive bacteria, lipoproteins from various 
microorganisms, glycosylphosphatidylinositol anchors of protozoans like 
Trypanosoma cruzi, zymosan from fungi, a phenol-soluble modulin from 
Staphylococcus epidermis and glycolipids from Treponema maltophilum (Takeda et 
al., 2003). Beyond these pathogen particles, TLR2 can recognize the 
lipopolysaccharide (LPS) preparations of Helicobacter pylori (Smith et al., 2003). 
However, wide spread function of TLR2 cannot be attributed to only TLR2. 
Dimerization of TLR2 with TLR1 and 6 provides its multiple pathogen particle 
recognizing talents. For instance, TLR2 cannot distinguish diacyl or triacyl 
lipopeptides by itself. Dimerization of TLR2 with TLR1 provides the diacyl 
lipopeptides recognition whereas dimerization with TLR6 ensures the triacyl 
lipopeptides recognition (Takeuchi et al., 2001; Takeuchi et al., 2002). Beyond 
dimerization with TLRs, TLR2 can also function with other kind of receptors. For 
fungal-derived component recognitions like β-glucan, TLR2 collaborate with lectin 
receptor family, herein dectin-1 (Gantner et al., 2003).  
 
The expression level of TLR2 is regulated positively by pro-inflammatory signals like 
TNF-α and negatively by anti-inflammatory signal molecules such as glucocorticoids 
(Hermoso et al., 2004). Correlated with its expression level, TLR2 activation is also 
regulated with respect to inflammatory signals.  
 
1.3.1.1.2.1.2. TLR3 
 
TLR3 recognizes the double-stranded (ds) RNA molecule of viruses. dsRNA is 
generated by a wide range of viruses during their life cycle. By finding out that 
dsRNA is recognized by TLR3, it was no doubt that TLRs have roles in host defense 
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against viral components as well as bacterial components (Alexopoulou et al., 2001). 
Upon dsRNA recognition, antiviral and immunostimulatory signals are activated. For 
antiviral alerts, type I interferons, IFN-α/IFN-β, are induced and synthesized. Besides, 
NF-κB signaling pathway is also activated in order to enhance immune response. 
TLR3 is found to be expressed by various immune system cells. For instance, 
dendritic cells, macrophages and even some epithelial cells are known to be 
expressing TLR3. However, as the most important director of antiviral responses, 
natural killer (NK) cells are the number one expressing TLR3. In addition to dsRNA, 
NK cells are responsive to polyriboinosinic polyribocytidylic acid (poly(I:C)) which 
is a synthetic dsRNA and induces the production of IL-6 and IL-8 as 
proinflammatory cytokines, IFN-γ as antiviral cytokine (Schmidt et al., 2004).  
  
1.3.1.1.2.1.3. TLR4 
 
Lipopolysaccharide (LPS), the major part of Gram-negative bacteria outer membrane, 
is the ligand for TLR4, the first defined human TLRs. The ligand for TLR4 is 
revealed out by the hyposensitivity studies to LPS when point mutations were 
introduced to this receptor (Hoshino et al., 1999). Within the last decade, it was 
found out that like TLR2, TLR4 has more ligands than one. For instance, taxol from 
Taxus brevifolia (Kawasaki et al., 2000) and respiratory syncytial virus fusion 
protein (Kurt-Jones et al., 2000) are other ligands for TLR4. What’s more, 
endogenous ligands, like heat shock proteins (HSP60, HSP70) at high concentrations 
were also activating TLR4 signaling pathways (Cohen-Sfady et al., 2005; Takeda 
and Akira, 2005).  
 
Just like TLR2 functioning, TLR4 has to cooperate with some accessory molecules 
in order to recognize LPS. LPS cannot directly bind to TLR4. First, it has to bind 
LPS-binding protein (LBP) which is found in the serum. Then, this serum protein 
transfers the subunits of LPS to CD14, which functions as a co-receptor of TLR4. 
Finally, TLR4 comes next to CD14 to recognize LPS particles and start down-stream 
signaling with the help of MD-2 (Shimazu et al., 1999; Wright et al., 1989).     
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1.3.1.1.2.1.4. TLR5 
 
Besides cell wall or genetic elements of bacterial organisms, some kinds of bacteria 
require flagellum for mobility. Therefore, subunits of flagellum, flagellin, provide a 
good recognizing agents for host defense. TLR5 does the flagellin recognizing duty 
of the innate immune system (Smith et al., 2003). The flagellin recognition induces 
inflammatory cytokine production such as TNF-α and IL-8.  
 
1.3.1.1.2.1.5. TLR7 and 8  
 
TLR7 and TLR8 have a close relativity since they are structurally conserved relative 
to each other. The discovery of ligands for these TLRs came during the approved 
treatment of viral infections. The synthetic compounds imidazoquinolines were the 
first to be defined as causing anti-viral activity upon administration (Hemmi et al., 
2002). It was shown that both TLRs were expressed; however, TLR8 was 
unresponsive to ssRNA in mice (Akira et al., 2006).  Upon induction of TLR7 and 8 
with imidazoquinolines and ssRNA, antiviral cytokines was found to be produced. 
These cytokines are synthesized upon activation of interferon regulatory pathways 
like IRF3 and IRF6 (Ito et al., 2005; Kawai et al., 2004).  
 
In the last decades, it was discovered that host cells also produces ssRNA. However, 
these ssRNAs, miRNA and siRNA, did not possess any danger signal for the host 
cells. This may explain why nucleic acid recognizing TLRs are localized inside the 
cell, on the endosomal membranes since self-derived ssRNAs are not delivered to 
endosomes (Lund et al., 2004; Takeda and Akira, 2007).   
 
1.3.1.1.2.1.6. TLR9 
 
One pivotal difference between bacterial genetic elements and mammalian genetic 
elements is the CpG dinucleotides. Although two groups have these sequences, 
bacterial DNA contains these CpG motifs in unmethylated form, which provides a 
basis for self/non-self discrimination of the immune system. TLR9 takes advantage 
of this difference and recognizes unmethylated bacterial CpG motifs. In vertebrates, 
the methylation of CpG motifs at cytosine residues ensures the self recognition and 
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does not lead to an immunostimulatory effect (Krieg et al., 1995). In TLR9-KO mice, 
CpG motifs from bacterial DNA do not cause any immunostimulatory response 
supporting the function of TLR9 in recognizing unmethylated CpG DNA (Hemmi et 
al., 2000). TLR9 expression has been found on B cells, natural killer cells and 
dendritic cells mostly. The expression of TLR9 is seen during the maturation, 
proliferation and cytokine secretion of related cell types (Krieg, 2000). In nature, two 
types of CpG DNA was discovered: CpG-B type and CpG-A type. Two types have 
differential effects and immunostimulatory potential on plasmacytoid dendritic cells 
(pDC) and B cells. The first identified CpG type is conventional CpG-B type which 
has the ability to induce pro-inflammatory cytokines like IL-12 and TNF-α. 
Differently from A type of CpG, conventional CpG type has phosphorothioate 
backbone without a poly (G) tail. Conversely, CpG-A type has its 3’ and 5’ ends 
linked to a poly (G) tail and build up with a phosphodiester/phosphorothioate mixed 
backbone. Another difference of these two types is the potential ability to induce 
IFN-α and IL-12 from pDCs. CpG-A type has a greater IFN-α induction potential, 
however it cannot induce as much IL-12 as CpG-B type could induce. In addition to 
this, CpG-A type cannot stimulate B cells (Gursel et al., 2002; Honda et al., 2005; 
Verthelyi et al., 2001). The potentiality differences between CpG types are due to the 
characteristics of target cells. Recently, pDCs are found to be expressing CXCL16 
which serves as a co-receptor along with the TLR9 in recognition of CpG-A type. On 
the contrary to pDCs, B cells do not express CXCL16 which results in no stimulation 
upon CpG-A type induction (Gursel et al., 2006). 
 
Collectively, it is possible to analyze the ligands for each TLR in Table 1.1. 
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Table 1.1 – Toll-like receptors and their ligands (Adopted from Takeda and Akira, 2007 with 
permission) 
 
1.3.1.1.2.2. Toll-Like Receptor Signaling Pathways 
 
TLRs bind specific ligands and signaling pathways are triggered. Through these 
signaling pathways, genes that are related with the inflammatory machinery starts to 
be expressed. Between ligand recognition and gene expression, there is an adaptor 
protein, myeloid differentiation primary response gene (88)-MyD88, which takes 
part in the TLR signaling. After ligand binding, intracellular domain of TLRs, called 
as TIR, associates with MyD88 and signals are transduced. The interaction of 
MyD88 is provided by the TIR domain of this molecule (Hemmi et al., 2002; 
Takeuchi et al., 2000). However, the signal transductions of TLRs are not always 
MyD88-dependent. For instance, TLR4 signaling can also occur via an alternative 
pathway; TRIF-dependent pathway. TIR-domain containing adaptor inducing IFN-β, 
TRIF, protein takes the role of MyD88 in this pathway (Youn et al., 2005). TLR3 
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and TLR4 can alternatively use this MyD88-independent/TRIF dependent pathway 
(Brint et al., 2002).  
 
As demonstrated in Figure 1.4, regardless of MyD88 dependency, stimulation of 
each TLR results in activation of NF-κB pathway, which in turn starts an 
inflammatory signaling cascade.   
Figure 1.4 - TLR signaling pathways (Adopted from Akira and Takeda, 2004 with permission). 
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2.  AIM 
 
Mesenchymal stem cells (MSC) are special progenitor cells and are distinct from 
adult stem cells in many ways. It was suggested by many studies that these cells 
undergoes lineage dependent differentiation depending on their micro-niche as well 
as self-renewal and homing capacity to damaged tissue sites. MSCs are also known 
to induce immunomodulatory effects and were indicated as a suitable therapeutic cell 
in GVHD capacity. Such diverse properties make MSCs a powerful tool in several 
therapeutic applications.  
 
Toll-like receptors (TLR) are expressed by the cells of the immune system that are 
evolutionarily selected to recognize conserved microbial byproducts. Recent findings 
suggest that in vitro generated MSCs express some of these pathogen recognition 
receptors raising the debate with regard to their immunosuppressive character. We 
reasoned that in order to broaden the therapeutic potential in addition to better 
understand MSCs biology, there is a need to describe the interplay between MSC and 
TLR interaction. 
 
In this context, present study was designed to pursue TLR mediated activation of 
MSCs and understand its impact on differentiation and immunomodulatory potential.  
 
This study is planned to be conducted in three main parts: In the first part, our goal 
was to determine the expression levels of TLRs by MSCs. Next the effect of TLR 
ligand addition on the adipogenesis was assessed. In the second part, migration 
capacity of these stem cells in the presence or absence of TLR ligands as well as 
their proliferation was investigated. Finally, immunomodulatory potential of MSCs 
either alone or in combination with spleen cell co-cultures in the presence or absence 
of different ligand was investigated.  
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3. MATERIALS AND METHODS 
 
3.1. MATERIALS 
 
3.1.1. Reagents 
 
MesenCult® (STEMCELL Technologies, Canada) was the main culture media used 
during the mesenchymal stem cell isolation procedure and culturing. In addition to 
this, RPMI1640 and low glucose DMEM and supplementary solutions of these 
media were all from Hyclone (USA).  
  
TRI Reagent (Trizol®), used for manual RNA isolation, was from Invitrogen (USA). 
DyNAmoTM cDNA Synthesis kit, DyNAzyme™ II PCR Master Mix for PCR was 
obtained from Finnzymes (Finland). All primers for PCR (designed), were purchased 
from Αlpha DNA (Canada). 50 bp DNA ladder was purchased from Jena Bioscience 
(Germany). 
  
Unlabeled or biotinylated monoclonal antibodies against IL-6 or IFN-γ were 
purchased from Thermo Scientific (previously known as Endogen, Pierce (USA). 
Recombinant cytokines used for standard curve preparations during cytokine 
quantitation and streptavidine-alkaline phosphatase (SA-AKP) were purchased from 
Endogen, Pierce (USA). Substrate for alkaline phosphatase p-nitrophenyl phosphate 
disodium salt (PNPP) was purchased from Thermo Scientific (USA).  
 
3.1.2. Toll-Like Receptor Ligands and Oligodeoxynucleotides 
 
Throughout this study, during the stimulation assays of co-cultured splenocytes or 
induction of MSCs to undergone differentiation following TLR ligands were used. 
Their sources and specifications were listed below: i) peptidoglycan (PGN, TLR2L 
or TLR2/6L) isolated from B. subtilis were from Fluka, (Switzerland), ii) 
lipopolysaccharide (LPS; TLR4L) isolated from E. coli were from Sigma, (USA), iii) 
poly inosinic acid:cytidylic acid (p(I:C), TLR3L) were received from Amersham, 
(UK), iv) a modified adenine base, R848, known as imiquimod that was developed 
by 3M company (TLR7/8L) was purchased from Invivogen (USA) and v) 
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immunostimulatory CpG motif expressing single stranded short ODNs (TLR9L), 
immunosuppressive telomeric repeat unit expressing ODNs (as a TLR antagonists) 
or control ODNs (flip CpG dinucleotides) were purchased from Alpha DNA 
(Canada), and some sequences (i.e. A151) were kindly provided by Dennis M. 
Klinman (NCI/NIH, USA).  
 
3.1.3. Standard Solutions, Buffers, and Culture Media  
 
The detailed information about the ingredients and preparations of common 
laboratory used buffers, sterile standard solutions and several other culture media 
used in the present work is presented in Appendix A (please refer to get further 
details).  
 
3.2. METHODS 
 
3.2.1. Maintenance of animals 
  
This M.Sc. thesis work was carried out using two different experimental animals, 
namely, rat and mice. Throughout the animal experiments, different organs of adult 
male Sprague-Dawley rats (6-9 months old) and adult male C57BL/6 mice (3-6 
months old) were used. These animals were sustained under controlled ambient 
conditions (22±2°C) with a cycle of 12 hrs light/dark cycles. They were fed ad 
libitum. Animal procedures employed throughout this thesis were approved by 
Bilkent University Animal Ethical Committee (Bil-AEC).  
 
3.2.2. Isolation and culture of Rat & Mouse Mesenchymal Stem Cells 
 
For bone marrow (BM) isolation, the animals were sacrificed by cervical dislocation. 
Next, the femur and tibia bones of both legs were removed and cleaned off muscles 
and adipose tissues. The ends of bones were cut with a bone cutting forceps and BM 
was flushed with pre-warmed DMEM media supplemented with 5-10 % FBS and 1% 
penicillin/streptomycin (Hyclone, USA). The flushing of BMs was done using a 10 
ml syringe in the case of rat bone marrow and a 5 ml syringe during mouse BM 
isolation. After collecting BM cells in a 50 ml falcon, they were centrifuged at 1500 
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rpm for 8-10 mins at RT. Then, the supernatant was sucked with glass pasteur pipette 
travelling the inner wall of falcon tube in order to remove any connective or adipose 
tissue. The pellet was mildly dislodged with the help of a pin rack and washed 3x 
with warm DMEM. At the end of washing steps, BM cells were counted and seeded 
into T75 flasks with a concentration of not more than 25x106 cells/flask (2-
2.5x106/ml).  
 
3.2.3. Cell Culture 
 
3.2.3.1. Preparation of Single Cell Suspension of Mouse Spleen 
Cells 
 
Male C57BL/6 were sacrificed by cervical dislocation and spleens were removed in 
aseptic conditions and the whole organ was transferred into 2-3 ml warm DMEM (or 
in some cases RPMI media) containing 5-10% FBS in 6-well plates. In order to 
obtain single cell suspension, under lamin-air hood, spleens were first smashed with 
a sterile syringe plunger back moving in circular directions. They were then collected 
in 15 ml falcon tubes. The cells were centrifuged at 1500 rpm for 8-10 mins, washed 
twice with warm media and were resuspended in 5% oligo FBS supplemented 
RPMI-1640 medium (Hyclone, USA). Single cell suspensions of splenocytes were 
counted and used for further assays.   
 
3.2.3.2. Adjusting the Cells Following Counting 
 
A sample of 10 µl volume of single cell suspension of any intended cell source was 
transferred on a Neubaer cell counting chamber and covered by the help of a cover 
slip (please see figure 1 for the counting and cell number estimation strategy). Cells 
were counted, and the total cell number was computed. Based on the total cell 
number extracted after each procedure, cell populations were adjusted to required 
cell concentrations. Normally, for proliferation or of cytokine secretion detection 
assays 2x106/ml cells were harvested.  
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Figure 3.1 - Neubaer cell counting chamber 
 
Since 1 mm2 area of this chamber has a volume of 0.1 mm3, the total number of cells 
in 1 ml was calculated as follows.  
(Cell number in 4 little square x 4) x 104 x Dilution factor = Total cell number/ml  
 
 
 Cell number in 0.1 mm3 volume 
  
3.2.3.3. Stimulation with Toll-Like Receptor Ligands  
 
The final concentrations of TLR ligands for stimulation assays were presented in 
Table 3.1.  
 
Table 3.1 - The final concentrations of TLR ligands and ODNs used 
 
TLR Ligands and/or ODNs Final concentrations 
PGN : TLR2L or TLR2/6L 5 µg/ml 
p(I:C) : TLR3L 20 µg/ml 
LPS : TLR4L 5 µg/ml 
R848 : TLR7/8L 5 µg/ml 
CpG DNA : TLR9L 1 µM 
Control ODN : CpGflip ODN 1 µM 
A151  1 µM 
 
If any  
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3.2.4. Quantification of Gene Expression at Transcript Level 
 
3.2.4.1.   Total RNA Isolation and Quantification 
 
In cell culture if adherent, cells were trysinized, collected and centrifuged at 1500 
rpm for 5 mins. After sucking supernatant, 1 ml TriZol® reagent (approx. over 107 
cells) was added onto the cell pellet, gently pipetted until viscous, pink milkish 
homogenous solution appears. It was immediately transferred into an eppendorf tube. 
At this step, dissolved cell pellet in TriZol® reagent could be stored up to a month at -
80°C if immediate RNA isolation was not necessary. Alternatively, RNA isolation 
could be continued by the of 0.2 ml chloroform. At this stage the tube must be hand-
shaken vigorously for 15 secs. Following incubation at RT for 3 mins it was 
centrifuged at 13200 rpm for 17 mins at 4°C. At the end of centrifugation, the 
mixture was separated into three different layers. RNA presents at the top transparent 
liquid phase. With great care, this phase (>600 µl) was transferred into a new tube 
and 500 µl isopropanol was added and the solution was mixed by gentle up/down 
movements. It was incubated at RT for 10 mins and centrifuged again at 13200 rpm 
for 17 mins at 4°C. Supernatant of this mixture was sucked and 1 ml 75 % ethanol 
was added, gently mixed to dislodge RNA pellet and spin down at 8000 rpm for 7 
mins. After removal of the supernatant, second washing was performed with 1 ml of 
99.9 % ethanol. Centrifugation was repeated as done for the first wash and the liquid 
was discarded. The RNA pellet was left for drying at under lamin-air flow hood. Air-
dried pellets were dissolved in 40 µl nuclease-free ddH2O (Hyclone). The dissolving 
process should be done by pipetting for several times in order to obtain a 
homogenous RNA solution. The OD measurement of RNA was done with the 
spectrophotometer NanoDrop® ND-1000 (NanoDrop Technologies, USA) with 1 µl 
of RNA solution. The quality of RNA was determined using OD260/OD280 ratio that 
should be between 1.8 and 2.0. RNA solution outside of this OD measurement range 
indicates contamination (possibly coming from DNA, protein or phenol) these 
samples must be either re-purified or discarded. The isolated RNA samples were 
stored at -80°C until for further use.  
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3.2.4.2. cDNA Synthesis 
 
cDNAs were synthesized from isolated RNA samples with the cDNA synthesis kit 
according to the manufacturer’s protocol. 1 µg of total RNA and 1 µl Oligo (dT) 
primer was completed to 8 µl with ddH2O.  This mixture was pre-denatured at 65°C 
for 5 mins in order to get rid of the secondary RNA structures. After pre-denaturation 
the mixture was incubated on ice for 3 mins. Then, i) 10 µl RT Buffer (supplemented 
with dNTP mix and 10 mM MgCl2) and ii) 2 µl M-MuLV RNaseH RT (it also 
contains RNase inhibitor) were added. The reaction mixture, in 0.2 ml PCR tube was 
placed in MJ Mini Thermocycler, (BIORAD, USA) and incubated at 25°C for 10 
mins, 40°C for 45 mins, 85°C for 5 mins and 4°C for 10 mins. The synthesized 
cDNA samples were stored at -20°C for further use.  
 
3.2.4.3. Primers Designed for RT-PCR Studies 
 
All the primers used in this study were designed using Primer3 Input v.0.4.0 program 
(http://frodo.wi.mit.edu/primer3/) and the related gene sequences of rat and mouse 
were retrieved from Ensembl™ and Pubmed databases. In Table 3.2, rat, and mouse 
primer sequence details of TLRs and their PCR product sizes are presented. 
 
Table 3.2 - Rat* and mouse* primer set sequences and their expected product sizes 
 
Primer  
Name 
Direction Sequence Product 
Size 
rGAPDH F 
R 
5’-AGACAGCCGCATCTTCTTGT-3’ 
5’-CTTGCCGTGGGTAGAGTCAT-3’ 
207 bp 
rTLR1 F 
R 
5’-ACCTTCCTGGATGTGGAGCC-3’ 
5’-CCTGCAGTGGGGTTCCCTTA-3’ 
261 bp 
rTLR2 F 
R 
5’-CAAACTGGAGACTCTGGAAG-3’ 
5’-CTAAGAGCAGGATCAACAGG-3’ 
246 bp 
rTLR3 F 
R 
5’-GGGTCAACTCAGGATACTTG-3’ 
5’-AAGTCCTCGTTCAGGTTGG-3’ 
285 bp 
rTLR4 F 
R 
5’-CTAGCCGTCTTCAATCTGAC-3’ 
5’-ACACTGACCACCGATACACT-3’ 
215 bp 
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rTLR5 F 
R 
5’-AGAGGCTCCTACTCAGCTTC-3’ 
5’-AGAGTCCACAGTCAAACAGC-3’ 
249 bp 
rTLR6 F 
R 
5’-GAGCCTTCAGTAGCCTTTCT-3’ 
5’-GCTGTCTGGGTAATCACATC-3’ 
224 bp 
rTLR7 F 
R 
5’-CCCTTGAGAGAGCTGCGGTA-3’ 
5’-CTTTCCATGGTCCTGCTGGC-3’ 
236 bp 
rTLR9 F 
R 
5’-CATGGTCAGGTGTAAGAACC-3’ 
5’-CAGGTCCAGCTTGTTATAGG-3’ 
208 bp 
rTLR10 F 
R 
5’-GGCTGCTAACTTCTGGGTGC-3’ 
5’-TGTGGTCCCGACTAGCCATC-3’ 
272 bp 
mGAPDH F 
R 
5’-GTATGCCTCGGTCGTACCA-3’ 
5’-CTTCTGCATCCTGTCAGCAA-3’ 
450 bp 
mTLR1 F 
R 
5’-TTTGGGGGAAGCTGAAGACATC-3’ 
5’-CTTCGGCACGTTAGCACTGAGAC-3’ 
410 bp 
mTLR2 F 
R 
5’-TCTCTGGGCAGTCTTGAACATTTG-3’ 
5’-CGCGCATCGACTTTAGACTTTG-3’ 
320 bp 
mTLR3 F 
R 
5’-GGGGCTGTCTCACCTCCAC-3’ 
5’-GCGGGCCCGAAAACATCCTT-3’ 
250 bp 
mTLR4 F 
R 
5’-TGCCGTTTCTTGTTCTTCCTCT-3’ 
5’-CTGGCATCATCTTCATTGTCCTT-3’ 
240 bp 
mTLR5 F 
R 
5’-TGGGGCAGCAGGAAGACG-3’ 
5’-AGCGGCTGTGCGGATAAA-3’ 
380 bp 
mTLR6 F 
R 
5’-GCCCGCAGCTTGTGGTATC-3’ 
5’-GGGCTGGCCTGACTCTTA-3’ 
650 bp 
mTLR7 F 
R 
5’-TTAACCCACCAGACAAACCACAC-3’ 
5’-TAACAGCCACTATTTTCAAGCAGA-3’ 
700 bp 
mTLR9 F 
R 
5’-GATGCCCACCGCTCCCGCTATGT-3’ 
5’-TGGGGTGGAGGGGCAGAGAATGAA-3’ 
430 bp 
* “r” stands for rat and “m” stands for mouse primers.  
  
For rat characterization of MSCs, PCR products of several CD markers were studied. 
The primer sequences of CD markers for and their PCR product sizes are given in 
Table 3.3. 
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Table 3.3 - Rat CD marker primer set sequences and their expected product sizes 
 
3.2.4.3.1. PCR Studies for Rat and Mouse 
 
Throughout this work, in order to assess the changes in the gene levels of several 
related procedures, PCR analyses were extensively used. These PCR set-up 
conditions and reactions were summarized in Tables 3.4 and 3.5 (please review for 
details).  
 
 
 
 
 
Primer  Direction Sequence 
Product 
size 
rCD11b Forward 
Reverse 
5’-GCTGGGAGATGTGAATGGAG-3’ 
5’-TGATGCTGGCTACTGATGCT-3’ 
113 bp 
rCD29 Forward 
Reverse 
5’-ACTTCAGACTTCCGCATTGG-3’  
5’-GCTGCTGACCAACAAGTTCA-3’ 
190 bp 
rCD34 Forward 
Reverse 
5’-TGTCTGCTCCTTGAATCT-3’ 
5’-CCTGTGGGACTCCAACT-3’ 
281 bp 
rCD45 Forward 
Reverse 
5’-ATGTTATTGGGAGGGTGCAA-3’ 
5’-AAAATGTAACGCGCTTCAGG-3’ 
175 bp 
rCD71 Forward 
Reverse 
5’-ATGGTTCGTACAGCAGCAGA-3’ 
5’-CGAGCAGAATACAGCCATTG-3’ 
182 bp 
rCD73 Forward 
Reverse 
5’-GAACTTGGGAGGGAGGAGAG-3’  
5’-CATTGGCAGGAAGAGAGGAG-3’ 
282 bp 
rCD90 Forward 
Reverse 
5’-CCAGTCATCAGCATCACTCT-3’  
5’-AGCTTGTCTCTGATCACATT-3’ 
374 bp 
CD105 Forward 
Reverse 
5’-CGGGAGGTGTTTCTGGTCT-3’ 
5’-GTGTCTGGGTTCGTGGTTG-3’ 
331 bp 
rCD166  Forward 
Reverse 
5’-CTTTGTTCTGGGAGTGGCTG-3’  
5’-GGTGTTGCCGTATGTGTTTG-3’ 
303 bp 
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Table 3.4 - PCR Reaction Ingredients and Amounts 
 
Reaction Ingredients Volume 
cDNA 1 µl 
2X DyNAyzme™ II Master Mix (Finnzymes)* 12.5 µl 
Forward Primer (from 10 pmol stock) (Αlpha DNA) 1 µl 
Reverse Primer (from 10 pmol stock) (Αlpha DNA) 1 µl 
Nuclease-free ddH2O (Hyclone) 9.5 µl 
Total volume 25 µl 
* 2x DyNAzyme™ II PCR Master Mix includes 0.04 U/μl DyNAzyme™ II DNA Polymerase, 
20 mM Tris-HCI (pH 8.8 at 25°C), 3 mM MgCl2, 100 mM KCl, stabilizers and 400 μM of 
each dNTP.   
Table 3.5 - PCR conditions 
 
PCR step Rat TLR 
primers 
Rat CD marker 
primers 
Mouse TLR 
primers 
Initial 
Denaturation 
95°C, 5’ 95°C, 10’ 95°C, 5’ 
Denaturation 94°C, 30’’ 94°C, 40’’ 94°C, 30’’ 
Annealing 55°C, 30’’ 60°C, 30’’ 60°C, 30’’ 
Extension 72°C, 30’’ 72°C, 40’’ 72°C, 1’ 
Final Extension 72°C, 5’ 72°C, 10’ 72°C, 10’ 
Number of cycles 30 cycle 23 cycle 30 cycle 
  
 
3.2.4.4. Agarose Gel Electrophoresis and Quantification of Band 
Intensities 
 
1.5% agarose gel was prepared during gel electrophoresis with 1x TAE buffer and 1 
mg/ml ethidium bromide solution was used. 25 µl of PCR samples were mixed with 
5 µl loading dye and 10 µl of this mixture were loaded to each well. To serve as a 
marker, 2 µl of low range DNA ladder (50-500 bp, Jena Biosciences, Germany) was 
loaded along with the gene products. Running conditions were set at 90 V power for 
a duration of 45 mins. Gel band intensities were visualized under UV 
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transilluminator (Vilber Lourmat, France) for a period of 5-10 msec. The gel images 
were stored by Chemicapture software (Vilber Lourmat, France). 
  
3.2.5. Flow Cytometry 
 
3.2.5.1. Fixation of Cells 
 
The analysis of cell surface markers were studied from fixed MSCs collected at 
different passages. In order to fix MSCs, the cells in T75 flasks were first washed 
with 1X PBS w/o magnesium and calcium (Hyclone, USA) for once and then 
trypsinized and left at 37°C for 1-2 mins. The trypsinization was blocked with 2% 
FBS supplemented DMEM, washed twice, and pooled in falcon tubes following 
centrifugation at 1500 rpm for 5 minutes. The remaining cell pellet was dislodged by 
the help of a pin rack, while vortexing (15 secs) 100 µl fixation medium (Fix & 
Perm®, Caltag Lab, USA) was added at RT. The fixation was terminated at the end 
of 15 mins by the addition of 2 ml PBS-BSA-Na Azide solution (20x fold of initial 
fixation solution amount). The cells were centrifuged at 1500 rpm for 5 mins, 
supernatants were sucked and onto the pellet fresh 1 ml PBS-BSA-Na Azide was 
added to resuspend the cell pellets. They were kept at 4°C until for further analysis 
by FACS. 
 
3.2.5.2. Cell Surface Marker Staining 
 
Freshly or previously fixed cells were spun down at 1500 rpm for 5 minutes and 
were distributed into different tubes planned for specific staining at a 100 µl aliquots. 
Onto cell pellet following centrifugation and removal of the residual supernatants, 1 
µl antibody of CD90-FITC (Abcam, USA), CD45-PE/Cy5 (Abcam, USA), CD29 
(Chemicon, USA), CD71 (Santa Cruz, CA, USA) and CD106 (Santa Cruz, CA, 
USA) as well as their proper isotype control abs, was added and tubes were labeled. 
At the end of 30 mins incubation in dark at RT, cells were washed twice with 2 ml 
PBS-BSA-Na Azide and centrifuged at 1500 rpm for 10 minutes. Finally, cells were 
resuspended in 400 µl PBS-BSA-Na Azide in FACS tubes and analyzed in FACS 
Calibur instrument (Beckon Dickinson, San Jose, USA).  
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3.2.5.3. Flow Cytometric Analysis of Cells 
 
The analysis of cells was done according to 20,000 event count with the FACS 
Calibur instrument (Beckon Dickinson, San Jose, USA). The channel choice, gating 
and compensation adjustments were done related to sample and staining properties. 
The analysis of acquired data was carried out using CELL QuestPro software 
(Becton Dickinson Immunocytometry Systems, San Jose, USA).  
  
3.2.5.4. Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) 
Assay 
 
The CFSE staining method is adopted from a previously published protocol paper 
(Parish et al, 2009). Cells were collected into a falcon tube and centrifuged at 1500 
rpm for 5 minutes. Cell concentration was adjusted to 106 cells/ml and resuspended 
in warm 1x PBS. CFSE, in 1x warm PBS, was adjusted to a final concentration of 5 
µM CFSE. For homogenous distribution of CFSE, special care was taken to pipette 
the solution following CFSE addition. The cells were incubated at 37°C for 10 mins. 
In order to stop the reaction, 10 ml of warm 10% low glucose DMEM was added, 
cells were centrifuged at 1500 rpm for 5 mins and supernatant was sucked. The 
desired amounts of cells were reseeded in flasks and stimulations were done 
according to regular stimulation protocol of TLR ligands in MesenCult® medium 
(Please see section 3.2.3.3 for more details). The cells were then left for 3 days of 
incubation at 37°C in CO2 incubator. The cells were then, fixed and studied for their 
proliferation rate in FACS Calibur instrument (Beckon Dickinson, San Jose, USA) 
and data were analyzed by CELL QuestPro software (Becton Dickinson 
Immunocytometry Systems, San Jose, USA).  
 
3.2.6. Differentiation of rat Mesenchymal Stem Cells with or without 
Toll-Like Receptor Ligands 
 
In order to differentiate the role of supplementing the conventional differentiation 
media with various TLR ligands, modified assay conditions were planned to include 
specific ligands. To address this effect, adipogenic or osteogenic media were 
supplemented with different ligands according to the concentrations stated in Table 
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3.1. These different treatments were then stained for specific differentiations, 
positive cells were counted, and photomicrographs were recorded at different time 
intervals. Recordings were carried out by a Nikon Coolpix 4500 digital camera 
attached to Nikon Eclipse TS100 light microscope.  
 
3.2.6.1. Adipogenic Differentiation Alone or in the Presence of 
Toll-Like Receptor Ligands 
 
At the end of MSC induction protocol, MSCs (at P0) in T75 flasks were trypsinized 
(0.025%, w/ EDTA) and reseeded in 24-well plates at a 7x104 cells/well. After 24 h 
MesenCult medium was removed and replaced with adipogenic induction medium 
(this includes, 1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 
100 µM indomethacin and 10 µg/ml insulin (all from Sigma-Aldrich) in 10% high 
glucose DMEM medium).  Similarly, wells containing adipogenic induction medium 
plus i) TLR2, ii) TLR3, iii) TLR7, iv) TLR9, and their proper control ligands were 
incubated (as the treatment groups) and the induction medium was replenished every 
other day. Adipogenesis was followed daily by microscopic investigations and 
staining was performed for a period of 3 weeks (at specific time intervals) with Oil 
Red O.  
 
3.2.6.1.1.  Oil Red O Staining for Adipogenic Differentiation 
Assessment 
 
At specified time points, 24-well plate was brought to bench and media was aspirated. 
The fixation of cells was done in 4% paraformaldehyde solution (Carlo Erba, Italy) 
for 40 mins at RT. After fixation, cells were washed gently with adequate amount of 
1X PBS for three times and rinsed with ddH2O for two times with great care. The 
cells were incubated in sufficient amount of Oil Red O Solution (Chemicon, CA, 
USA) and left at RT for 50 mins. At the end of 50 mins, the Oil Red O Solution was 
aspirated and cells were rinsed gently with for ddH2O three times. The cell nuclei 
were counterstained with Mayer’s Hematoxylin Solution (Sigma-Aldrich, USA) for 
two minutes. Following counterstaining, cells were rinsed with ddH2O for two times 
and left in 1-2 ml ddH2O for picture capturing.  
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3.2.6.2. Osteogenic Differentiation Alone or in the Presence of Toll-
Like Receptor Ligands 
 
The isolation and seeding of P0 MSCs was performed as described above (Section 
3.2.6.1.). The osteogenic induction medium consists of 10-7 M dexamethasone, 0.25 
mM ascorbic acid and 0.45 mM glycerophosphate-disodium pentahydrate (all from 
Sigma-Aldrich) in 10% high glucose DMEM medium. Similarly, TLR ligands 
mentioned in the section 3.2.6.1., were included in the osteogenic media, and 
osteogenesis was followed daily by microscopic investigations and staining was 
performed for a period of 2 weeks (at specific time intervals) with Alizarin Red.   
 
3.2.6.2.1.  Alizarin Red Staining for Osteogenic Differentiation 
Assessment 
 
At specified time points, 24-well plate was brought to bench and media was aspirated. 
The fixation of cells was done in ice-cold %70 EtOH for 1 h at RT. After fixation, 
cells were rinsed with adequate amount of ddH2O for two times. For staining, 
sufficient amount of Alizarin Red Stain (Chemicon, CA, USA) was added each well 
and left at RT for 30 mins. At the end of 30 mins, the stain was aspirated and cells 
were rinsed with ddH2O for four times. As a final step, 1-2 ml distilled water was 
added to each well and immediate analysis for osteogenesis was done.  
 
3.2.7. Migration Assay  
 
Rat mesenchymal stem cells at P3 were seeded at a confluency of nearly 80% into 6-
well plates in triplicates. The plates were checked every day and when cells reached 
near 100% confluency, it is crucial that cells must not be over confluent and a single 
layer of cells should be formed, with the help of a P1000 pipette tip “wounds” were 
generated. In order to have regular wounds, a ruler was used while generating 
wounds. Following wound generations, pictures of each group in triplicate 
experiment design were taken at 0 h just over the previously drawn horizontal lines 
at the back of the plates. Then, rMSCs were incubated in MesenCult® medium 
containing TLR ligands at concentrations previously calculated (see Table 3.1). After 
24 h incubation at 37°C in CO2 incubator, pictures of each group were taken in 
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triplicates for the same areas and medium containing proper TLR ligands were 
replenished. The plates were left for another 24 h incubation. At 48 h, pictures were 
taken for the same areas again and the experiment was terminated. The pictures were 
taken with Nikon Coolpix 4500 digital camera attached to Nikon Eclipse TS100 light 
microscope. The migration distances of rMSCs were calculated with ImageJ software 
(NIH, USA) by taking several measurements in the wound regions. The overall 
migrations for each group were given relative to the naive group containing only 
MesenCult® medium.  
 
3.2.8. Co-culturing of Splenocytes and mouse Mesenchymal Stem Cells 
with or without Toll-Like Receptor Ligands  
  
The TLR ligand and ODN stimulations were done according to the concentrations 
mentioned in Table 3.1. 
  
The co-culturing of MSCs with splenocytes was done in an increasing titration of 
splenocytes where MSC ratio but not the number was kept constant comparing to 
splenocytes. The counting of splenocytes and MSCs were done as described in 
section 3.2.3.2. and cells were distributed in 96 well plate with the starting 
splenocyte and MSC cell number being 25 x 104. The titrations of MSC to splenocyte 
were from 1:1 to 1:103 in triplicate for each group. Moreover, splenocyte alone and 
MSC alone groups were also studied as two groups with 25 x 104 and 5 x105 cell 
numbers in triplicate.  
 
In addition to co-culturing of splenocytes and MSCs, MSC alone titrations were 
studied in 96 well plates in triplicate in the presence of TLR ligands. MSC titrations 
were from 2.5 x 102 to 5 x 105.  
 
3.2.9. Enzyme Linked Immunosorbent Assay (ELISA) 
 
In order to check the early and late immunological responses in the case of cellular 
responses raised against TLR ligand inductions, (splenocyte alone, MSC alone, or 
co-culture experiments) IL-6 and IFN-γ cytokines were studied by in house 
developed sandwich ELISA. 
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3.2.9.1.  Collection and Storage of Cell Supernatants Following 
Treatment with Toll-Like Receptor Ligands 
 
At the end of 40 h incubation time, 96 well plates were centrifuged at 1275 rpm (200 
g) for 6 minutes and approximately 180 µl supernatant from each well was collected 
into a sterile 96 well cell culture plates. Cell supernatants were frozen down and 
stored at -20°C until for further use. 
 
3.2.9.2. Cytokine ELISA 
 
Coating of Immulon 2HB plates (Thermo Labsystems, USA) were done with 
monoclonal antibodies against mouse cytokines IL-6 and IFN-γ. The concentrations 
of antibodies were adjusted to 10 µg/ml in 1x PBS and 50 µl of the antibody 
solutions were distributed in each well. For coating, incubations were done either at 
+4°C overnight or 4 h at RT. Following coating, anti-cytokine solution was decanted 
and blocked with 200 µl blocking buffer for 2 h at RT (alternatively at +4°C 
overnight). Washing step was done with ELISA wash buffer 5x with 5 mins 
incubation intervals after each wash. At the end of washing, plates were rinsed with 
ddH2O for twice and dried by tapping. Next, collected supernatants were brought to 
RT by thawing on the bench and layered on the 96 well plate at a volume of 
50ul/well for each cytokine. Corresponding recombinant cytokines were serially 
distributed. Normally for a cytokine standard 1000 ng/ml concentration was diluted 
serially by two-fold with 1x PBS for 11 times. Plates were left at RT for 2 h or at 
+4°C overnight. After this step, plates were washed and dried as described before. 
Subsequently, biotinylated anti-cytokine antibodies were prepared in T-cell buffer (at 
a ratio of 1:1000 dilution) and distributed over the wells 50 µl to each well and 
incubated for another 2 h. Washing steps repeated and streptavidin alkaline-
phosphatase (SA-AKP, Pierce, IL, USA) was (in T-cell buffer, 1:1000) added to the 
plates as 50 µl/well. After 1 h incubation at RT, washing and drying steps were 
repeated. Finally, PNPP substrate (Pierce, USA) was prepared as 1 tablet/4 ml 
ddH2O + 1 ml buffer and layered over the wells as 50 µl portions. Yellow color 
development was followed continuously and multiple OD readings (at 405 nm) were 
recorded by ELISA reader (Molecular Devices). The OD measurements were 
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analyzed by SoftMax Pro v5 software. The color development was terminated when 
4-parameter standard curve was obtained. 
 
3.2.10. Statistical Analysis 
 
Statistical analysis for the treatment groups were conducted by SIGMA-STAT 
anaysis software. Student`s t-test between control (or naïve) vs each treatment group 
(two-tailed unpaired comparison) was done for assays. P<0.05 was considered 
significant throughout these studies.  
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4. RESULTS 
 
4.1. Rat Mesenchymal Stem Cells 
 
Mesenchymal stem cells (MSCs) are localized in the bone marrow along with other 
stem cell types such as hematopoietic stem cells. Thus following isolation, 
characterization of these mesenchymal stem cells is a strictly essential step for 
studying these stem cells. Characterization could be done with a number of methods. 
One of these methods is following the morphological changes of these cells during 
the isolation period. MSCs have fibroblast-like morphology at the end of 14 days. 
Moreover, these stem cells are found in colonies in flasks and frequently proliferate 
from a single progenitor cell and finally form a colony. Another characterization 
method is the surface marker expression analysis. For certain CD markers these stem 
cells are positive whereas for some they are negative. Last but the most primitive 
characterization method is the property of plastic adherence. Contrary to 
hematopoietic stem cells or erythrocytes which are present in the bone marrow, 
mesenchymal stem cells are adherent and could adhere to plastic. On the basis of 
these three criteria stated by the (Dominici et al, 2006) rat and mouse mesenchymal 
stem cells were characterized during and/or after the isolation process from bone 
marrow of related animal. 
 
4.1.1. Characterization of Rat Mesenchymal Stem Cell  
 
Isolation and generation of rat mesenchymal stem cells were performed as stated in 
Section 3.2.2. The characterization of rat mesenchymal stem cells was done 
according to their morphological changes during the isolation period, their surface 
marker expression was analyzed by RT-PCR and finally by flow cytometry, surface 
markers were analyzed.  
 
4.1.1.1. Transition from Bone Marrow to Mesenchymal Stem Cells 
during Culturing  
 
Since mesenchymal stem cells have the plastic adherency, in the first day of isolation, 
media was replenished to get rid of the swimming concomitant cell types like 
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hematopoietic stem cells and erythrocytes. After then, twice a week, media was 
replenished with fresh media until the end of 14 day isolation period.  
 
 
 
 
 
 
 
 
 
 
Progenitor cells potentially committed to undergo MSC generation at day 1 (A), day 3 (B) 
 
 
 
 
 
 
 
 
 
 
As the isolation period proceeds, fibroblast-like MSCs and their colonies are able to be clearly 
observed at day 8 (C), day 14 (D)  
 
 
In the Figure 4.1, the phases of mesenchymal stem cell generation from rat bone 
marrow cells could be seen during the isolation period. From the first day of isolation, 
cells with stem cell potential propensity start to form colonies and in the following 
days of isolation, these cells start to get a much more fibroblastic shape. By the way, 
in the first day picture, erythrocytes could be observed in pinkish color as small 
groups. With the media replenishment, this contaminating cell group and others are 
eliminated with the plastic adherency property of MSCs.        
Figure 4.1A-D - Photomicrographic investigations of rat bone marrow in isolation phases (Mag = 10X)
 37 
 
However, at the end isolation procedure, the remaining cell population is never a 
pure mesenchymal stem cell population. This is why, there are also cells present in 
bone marrow that can adhere to plastic. In order to diminish these cell types as much 
as possible, passaging of mesenchymal stem cells was done. In the Figure 4.2, 
passage 1 (from now on, passage no will be stated as P#, P2 e.g.) and passage 2 
mesenchymal stem cell populations could be observed. 
 
 
 
 
 
 
 
 
 
   MSC colonies during different passages. 
 
 
 
4.1.1.2. PCR Results and Gel Images Over Passages 
 
4.1.1.2.1. CD Marker Expression Panels 
 
It is clear that having a pure MSC population is necessary whilst contaminating cells 
would affect the potential and function of these cell populations. Along with this, 
passaging over and over would have side effects like stem cells would lose some of 
their stem cell-like potential (Wall et al., 2007; Yu et al., 2010). At this point, 
characterization of mesenchymal stem cells would be done with surface marker 
expression analysis to see how pure your cell population is. For mesenchymal stem 
cells, CD90, CD71 and CD105 surface marker expressions must be positive whereas 
CD11b as macrophage marker, CD34 and CD45 as hematopoietic stem cell marker 
expressions must be negative. Besides, it is a hard issue to differentiate MSCs from 
other cell types so recently numerous candidate MSC marker proteins were published 
in literature. Since it is sufficient to check for certain markers which are widely used 
Figure 4.2A and 2B – Appearance of MSC colonies at different passages; left picture shows P1 
MSCs, right one P2 MSCs. (Mag = 10X) 
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in the literature for MSC characterization, we also checked for the positive 
expression of CD29, CD71, and CD166 over the different passages of MSC 
populations.  
 
Figure 4.3 - CD marker expression panel over passages for characterization 
 
In Figure 4.3, CD marker expression panels of P0, P3, P6, P9 and P12 MSCs are 
seen. CD90 is a reliable stem cell marker and throughout the passages, it is the most 
strongly expressed CD marker. There is a faint CD45 band observed in P0 MSC 
which shows that MSC population is still heterogeneous at the end of isolation 
procedure. However, with the passaging, this band goes off. This situation could also 
be observed in CD11b expression. Besides, positive markers for MSCs are expressed 
with a high stability. Throughout the passaging; expression of markers CD29, CD71, 
CD73, CD90, CD105 and CD166 could be observed with slight exceptions.   
 
4.1.1.2.2. Toll-Like Receptor Expression Panels 
 
During all the studies carried out in this thesis, two main materials were the key 
players. Toll-like receptors (TLRs) are one of them and so it is important to report 
the TLR expression of mesenchymal stem cells. In the Figure 4.4, TLR expression of 
some MSC passages could be observed.  
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Figure 4.4 - TLR expression panel over different MSC passages 
 
TLR expression profiles of MSC passages do not show fluctuations except P0 MSC. 
The difference in TLR expression of P0 among other passages should be a side effect 
of contaminating cell populations present in P0 MSC. In general, TLR3 expression is 
the strongest between TLRs while others show a basal expression and all together, 
TLRs do not show significant change over passages.    
 
4.1.1.3. Flow Cytometry Analysis 
 
Although PCR analysis of MSC characteristic genes provided valuable information 
with regard to their conversion to MSC from progenitor BM cells, detailed protein 
expression of the signature CD markers at the MSC surface by FACS analysis leaves 
very little doubt about the status of the MSC population recovered after successive 
passages. 
   
Thus, along with RT-PCR expression of CD markers (CD90, CD45 and CD106) by 
flow cytometric analysis including their proper isotype controls were conducted for 
MSCs at different passages. It was decided to use CD90 as the positive marker and 
CD45 and CD106 as a negative marker.   
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As presented in Figure 4.5, CD marker expressions at P4 as expected, demonstrated 
that BM derived MSCs in culture is highly positive for CD90 and negative for CD45 
and CD106, confirming previous PCR findings. In Table 4.1, % positivity for each 
tested surface expressed CD markers at different MSC passages is summarized. 
Table 4.2 provides the MFI of each CD marker studied at different MSC passages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 - Representative analysis plots of CD markers for P4 
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Table 4.1 % positive of CD marker expressions at different passages 
 
 CD90* CD45** CD106** 
 Isotype  Cell  Isotype  Cell Isotype  Cell  
P0 1.0±0.3 30.2±15.4 0.3±0.2 0.5±0.3 0.9±0.2 1.1±0.4 
P2 1.4±0.2 56.5±10.3 0.6±0.4 1.9±0.9 0.6±0.5 0.7±0.6 
P3 1.9±1.0 79.6±4.9 1.0±0.03 4.3±0.6 1.0±0.01 1.1±0.1 
P4 3.0±1.0 88.6±3.2 2.7±0.03 3.4±0.6 2.1±0.3 3.2±1.4 
P6 3.0±1.0 78.6±5.3 3.0±1.0 3.0±0.9 2.9±0.9 3.3±1.9 
P8 2.6±1.2 71.9±27.5 2.3±1.2 4.7±0.7 1.8±0.3 2.3±0.1 
P10 2.6±1.2 71.9±8.5 2.7±0.03 3.4±0.6 2.1±1.1 2.8±1.3 
* indicates positive marker, ** indicates negative markers for rat MSCs. 
 
Table 4.2 – Mean Fluorescence Intensity (MFI) values of CD markers obtained by FACS analysis at 
different passages 
 
 CD90* CD45** CD106** 
 Isotype  Cell  Isotype  Cell Isotype  Cell  
P0 8.4±2.3 257.7±190 7.8±4.2 8.7±4.9 15.7±12.0 16.4±11.7 
P2 9.8±1.6 212±41.4 10.2±3.0 11.7±3.0 23.6±12.8 10.8±1.3 
P3 10.9±1.2 152±10.5 7.8±1.6 11.4±1.0 9.2±0.2 9.4±0.3 
P4 14.51±2.1 260.43±20 13.19±2.1 15.5±2.0 7.64±2.1 12.7±2.8 
P6 15.21±2.2 180.16±15 12.9±2.01 14.8±1.01 7.05±1.5 8.74±1.23 
P8 8.0±0.7 127.9±38 4.8±1.1 6.6±0.8 5.5±0.7 6.5±0.3 
P10 8.87±1.0 133.69±6 4.65±0.67 5.18±0.87 6.2±0.55 7.3±0.4 
* indicates positive marker, ** indicates negative markers for rat MSCs. 
 
When taken together, Table 4.1 and 4.2 established that the characteristic surface 
marker expression (CD90+) increased substantially from P0 to P6 (up to ~ 90% 
positivity). These results suggested that the MSC generation protocol from rat BM 
indeed converted the progenitor cells into MSCs. 
 
The MFI measurement is an indication of the extent of CD90 protein expression at 
the MSC surface. As seen in Table 4.2 these values are consistent with % expressed 
surface CD marker values. The findings in this section revealed that MSC conversion, 
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as judged by their +ve and -ve CD marker expression from rat BM took place and 
their MSC characteristics were retained after successive passages. This is one of the 
hallmarks to obtain pluripotent MSC population and could be harnessed to 
differentiate into organ specific cell types (i.e. adipocytes, osteocytes, myocytes, and 
neurons) when culturing them in selective differentiation culture medium. 
 
4.2. Differentiation of Rat Mesenchymal Stem Cells in the presence or 
absence of Toll-Like Receptor Ligands 
 
4.2.1. Adipogenic Differentiation Studies with rat Mesenchymal Stem 
Cells at Passage 0 
 
One of the unique characteristics of mesenchymal stem cells is their ability to 
differentiate into different lineages. Differentiation of MSCs requires selective media 
supplemented with several compounds at specific concentrations. The incubation 
period is lengthy reaching up to several weeks for certain cells making this process 
not only lengthy but very expensive. Moreover, the conversion yields are not at the 
appreciable levels. Description of new media components that would significantly 
reduce differentiation time while increasing conversion yield is a critical issue in 
MSC field. Since earlier observations established that MSCs express certain TLRs 
(Figure 4.4 for details) we postulated that supplementing specific differentiation 
media with some of these TLR ligands might contribute to induce better MSC 
differentiation (i.e. reduced culture time as well as increased conversion yield).  In 
this part of the present study, we checked the effect of TLR2L, TLR3L, TLR7L and 
TLR9L addition on adipocyte and osteocyte generation. The differentiation studies 
were performed with different passages of rMSCs. This is to understand if the 
passage number has any effects on the differentiation capacity of MSCs in the 
presence and absence of TLR ligands. Adipocyte induction was continued with 
freshly made medium and replenishments were performed at two days intervals (with 
or without TLRL) throughout the course of three weeks.  
 
Under normal differentiation conditions, MSC to adipocyte conversion takes three 
weeks. By the fifth day of induction, cells grown under TLRL supplemented medium 
started to deposit small and shiny lipid droplets (data not shown) whereas these 
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inclusions were barely visible for the MSCs cultured in regular adipocyte medium. 
As the induction period continued, the numbers and the sizes of lipid droplets 
increased and filled up the cell cytoplasm (compare Figure 4.6 vs Figure 4.7). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the Figure 4.6, P0 rMSCs Oil Red O stainings are given at the end of week 1. 
These photomicrographs are presented based on the adipogenesis rates of each 
treatment. The quantitation of how much adipocyte was induced in the presence or 
absence TLR ligands were done by counting cells positive for Oil Red O stained 
lipid inclusions from four different areas representing the overall adipocyte 
generation for that well. According to these criteria, at the end of first week of 
induction, R848 (Fig 4.6A) gave the most adipogenic outcome and was followed by 
PGN, p(I:C), CpG and Control ODN (Fig 4.6B-E) as it can be seen normal 
adipogenic media (Fig 4.6F) performed the weakest of all. This feature seen for the 
adipogenic media is not surprising, since it requires 3 weeks to convert MSCs into 
adipocytes. 
 
TLR2L = PGN TLR3L = p(I:C) TLR7L = R848 > > 
TLR9L = CpG Control ODN Adipogenic medium only > > 
Figure 4.6 - P0 rMSC Oil Red O staining at the end of 1st week (Mag = 20X) 
A 
F E D 
B C 
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In Figure 4.7, the second week results of P0 rMSC adipogenic induction were shown. 
Comparing these results with the first week adipogenesis profiles, it is fair to say that 
PGN treated group significantly improved and led to near complete differentiation of 
the MSCs within two weeks (Figure 4.7, top left panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adipogenic induction medium was the weakest of all. Next to PGN, p(I:C), R848 
and Control ODN treated groups induced significantly better differentiation than 
adipogenic induction medium only group at the end of two weeks. The continuation 
of the experiment for another week was unnecessary, thus this set of experiment was 
decided to be terminated at week 2.  Figure 4.8 presents contribution of different 
TLR ligand supplement into adipose generation medium at the end of two weeks. As 
seen in this figure and supported by the photomicrographs presented in Figures 4.6 
and 4.7, several TLR ligands (PGN, p(I:C), and R848) significantly boosted 
adipogenesis rate and efficiency, compared to gold standard medium conventionally 
utilized to obtain adipose differentiation.  
 
 
 
 
> > TLR2L = PGN Control ODN TLR3L = p(I:C) 
> TLR9L = CpG  Adipogenic medium only  > TLR7L = R848 
Figure 4.7 - P0 rMSC Oil Red O staining at the end of 2nd week (Mag = 20X) 
A 
F E D 
B C 
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4.2.2. Adipogenic Differentiation Studies with rat Mesenchymal Stem 
Cells at Passage 3 
 
In order to further delineate the kinetics of adipogenesis in the presence of TLR 
ligands, another set of experiment using rMSCs at P3 was initiated. The stainings 
were selected to include shorter time intervals (i.e. d5, d8, d11 and d14). The detailed 
photomicrographs are presented in Appendix B-2 (please see page 93 for more 
details).   
 
Over the course of two weeks, data from Figure 4.9 revealed that R848 and CpG 
ODN supplemented media induced the highest number of adipogenesis from MSC 
started at P3. As seen in the Figure 4.10, cells at the end of week 1 that was cultured 
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Figure 4.8 - MSC differentiation (@P=0) in the presence or absence of TLR ligands. Culture media 
replenishment in two days intervals was conducted and adipogenesis was monitored by counting the 
cells positive for Oil Red O (* p < 0.05, comparing to “Medium only”). 
Figure 4.9 - Kinetics of rMSC differentiation (@P3) into adipocytes in the presence or absence of 
TLR ligands (see legend for Fig 4.8 for more details) (* p < 0.01, comparing to “Medium only”). 
* *
* *
*
* 
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in the presence of PGN gave the highest conversion of Oil Red O positive cells, but 
this trend changed by the end of week 2. Starting with P3 MSCs, R848 together with 
CpG ODN performed better than PGN (Figure 4.11). Consistent with to previous  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adipogenic medium only  TLR3L = p(I:C) > > Control ODN 
> > TLR7L = R848 TLR9L = CpG  TLR2L = PGN 
Figure 4.10 - Photomicrographs of rMSC (@P3) differentiated to adipocytes at D8 (Mag = 20X) 
Control ODN TLR2L = PGN > => Adipogenic medium only  
> > TLR9L = CpG  TLR3L = p(I:C) TLR7L = R848 
Figure 4.11 - Photomicrographs of rMSC (@P3) differentiated to adipocytes at week 2 (Mag = 20X)
A 
F E D 
B C 
A 
F E D 
B C 
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finding, adipose medium alone treated MSCs performed worst of all the tested 
groups at all times (compare Figures 4.8 with 4.9).  
 
Taking together, the findings obtained from P0 and P3 MSC revealed that Control 
ODN and adipose medium alone treated groups did not perform better than any of 
the tested four different TLR ligand throughout adipogenic inductions. These two 
adipogenesis experiments implicated that R848 is the best performing ligand. If one 
tries to rank the performances of these ligands (average of P0 and P3 studies) based 
on their induction capacity, the list appear like below: 
 
1 - R848=TLR7 Ligand 
2 - PGN= TLR2/6 Ligand 
3 - CpG ODN= TLR9 Ligand 
4 - p(I:C)= TLR3 Ligand 
 
Another observation worth mentioning is that the rate of adipocyte generation at the 
end of each week for both studies suggested that at the end of week 1 R848 induction 
was better if P3 MSCs are used rather than P0 MSCs (35% vs 18%, compare week 1 
values of Figures 4.8 and 4.9). This increased rate of conversion however, is lost by 
the end of week 2 and is not significant between different passages (~85% for both 
trials). 
 
4.2.3. Adipogenic Differentiation Studies with rat Mesenchymal Stem 
Cells at Passage 6 and Passage 9 
 
The adipogenic differentiation study in the presence or absence of different TLR 
ligands was designed to uncover two issues; i) rate and ii) efficiencies of 
adipogenesis at different MSC passages. The initial studies were carried out at P0 
and P3, we also aimed to follow adipogenesis of MSCs after several passages. In 
TLR expression studies, we observed that TLR expression wanes at later stages of 
MSC passages. To understand the effectiveness of ligand supplementation during 
adipocyte differentiation, MSCs at P6 and P9 were also followed (please see Figure 
4.12).  The photomicrographs of adipogenic differentiation along time are presented 
in Appendix B-2 (please see page 94 for more details). 
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As seen in Figure 4.12, p(I:C) led the highest induction at the end of two weeks of 
differentiation culture. Recalling the TLR gene expression profiles of MSCs at 
different passages, one would notice that by P6 receptor for p(I:C), (i.e. TLR3) 
expressed at much higher level than any other TLRs, supporting the data presented in 
Figure 4.12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 - Photomicrographs of rMSC at P6 differentiating into adipocytes at week 2 (Mag = 20X)
> > TLR9L = CpG TLR3L = p(I:C) 
TLR2L = PGN Adipogenic medium only Control ODN 
TLR7L = R848  
> > 
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Figure 4.12 - Kinetics of MSC differentiation into adipocytes at P6 in the presence or absence of TLR 
ligands (see Fig 4.8 legend for more details) (* p < 0.05, comparing to “Medium only”).  
*
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The Oil Red O staining of differentiated MSCs at P6 at the end of two weeks is 
presented in Figure 4.13. At P6 TLRL 2, 7, and 9 performed similar to each other but 
lower than p(I:C). Again, control ODN or adipose medium alone is very weak at the 
induction potential. 
 
Lastly, in this part of the study we investigated the adipogenic performance of the 
MSCs at P9. Among the MSC passages studied so far, this passage showed the 
slowest rate of differentiation, therefore, we have decided to extend the induction 
period up to three weeks. As seen in the Figures 4.14 and 4.15, the rates of 
conversion into adipocytes were very low compared to previous passages (compare 
Fig 4.8, 4.9, 4.12, with 4.14).  
 
 
As can be seen from Figure 4.14, the trend reached at the end of week 3 is only 
comparable to the differentiation rate seen at week 2 of MSCs used at P6. The 
induction rate of the MSCs at later passages is significantly delayed. Consistent with 
P6 findings MSCs at P9 initiated the highest adipogenic conversion when the 
medium is supplemented with TLR3 ligand (p(I:C)).  
 
The overall summary of the differentiation in the presence or absence of TLR ligands 
at the end of the induction period is summarized in the Table 4.3 
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Figure 4.14 - Kinetics of MSC differentiation into adipocytes at P9 in the presence or absence of TLR 
ligands (see Fig 4.8 legend for more details) 
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Table 4.3 - Overview of the adipogenesis from MSCs treated with different TLR ligand containing 
adipose differentiation medium 
 
 
: 
 
 
 
 
 
  
* T= Week 2, ** T= Week 3 
These set of experiments revealed that passage number is critical during adipocyte 
differentiation from MSCs. Furthermore, inclusion of certain TLR ligands in the 
differentiation media significantly facilitates adipogenic development at P<3. Our 
results strongly suggested that, it is possible to accelerate as well as increase the rate 
and efficiency of MSC adipogenesis by the addition of either TLR2 ligand, (a 
member of cell surface expressed TLR family), or TLR7 ligand, (a member of 
endosome associated TLR family) during early passages. For MSCs (i.e. P>6) 
undergoing differentiation, supplementing media with p(I:C) proved to be important. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rx Groups P0* P3* P6* P9** 
Medium Alone 337 203 82 72 
+ Control ODN 329 185 122 31 
+ PGN (TLR2L) 954 525 172 164 
+ p(I:C) (TLR3L) 6410 573 333 288 
+ R848 (TLR7L) 855 755 203 235 
+ CpG ODN (TLR9L) 306 854 194 134 
TLR9L = CpG > > Adipogenic medium only Control ODN 
> > TLR3L = p(I:C)  TLR7L = R848 TLR2L = PGN 
A 
F E D 
B C 
Figure 4.15 - Photomicrographs of rMSC at P9 differentiating into adipocytes at week 3 (Mag = 20X)
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4.3. RT-PCR Analysis of Differentiation Experiments  
 
4.3.1. RT-PCR Analysis of Lineage-Specific Genes 
 
While Oil Red O staining of MSCs at various time of incubation and visualizing their 
induction patterns under microscopic investigation is a substantial evidence for the 
generation of adipocytes, it is also necessary to demonstrate the expression of several 
key gene expression specific for different differentiation. During this study, 
differentiations in the adipogenic and osteogenic directions were assessed in the 
presence or absence of TLR ligands. Commitment of MSCs in the direction of organ-
specific differentiation was followed by RT-PCR. For adipocytes, i) lpl (lipoprotein) 
and ii) ppar-γ (peroxisome proliferator-activated receptor gamma) transcripts were 
selected as the lineage specific genes. For osteogenesis, i) alp (alkaline phosphatase), 
ii) oc-1 (osteocalcin-1) and iii) runx (Runt-related transcription factor 1) were 
selected as the lineage-specific marker genes.   
 
In the Figure 4.16, agarose gel images of the effect of TLR ligand addition on LPL 
and PPAR-γ message expression during adipocyte differentiation of P0 and P3 MSCs 
are presented. During MSC to adipogenic differentiation at P0, from the gel images 
an increased level of LPL and PPAR-γ expression is observed. This is mainly 
mediated by R848 and CpG treatment (please see Figure 4.16, top panel).  
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Figure 4.16 - Adipocyte specific gene expression panels of P0 and P3 rMSCs supplemented with 
different TLR ligands 
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Although a strong lpl and weak ppar- expressions were observed during P0 MSC 
commitment into adipogenesis when incubated in adipose only medium, the 
expressions of these genes were significantly very low when P3 MSC were utilized 
(compare upper left panel with lower left in Figure 4.16). Involvement of TLR 
ligands in the adipose generation medium significantly improved lpl expression and 
also low but detectable level of ppar-  expression was induced. This evidence 
indicated that TLR ligands positively impact adipogenesis at P3 (please see lower 
panel for details).  
 
In this part of the thesis, in addition to adipogenesis, osteogenic differentiation of 
MSCs were also studied. The lineage-specific gene expressions from TLR ligand 
treated groups were analyzed by RT-PCR for MSCs at P0 and P3 passages. Results 
demonstrated that at P0 addition of TLR ligands (except p(I:C)) induced substantial 
but non-significant improvement of the alp, oc-1 and runx transcripts compared to 
osteogenic induction medium group (please see Figure 4.17 for more details) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osteogenesis in the presence and absence of TLR ligand supplemented 
differentiation medium was also assessed for the MSCs at P3 by RT-PCR (Figure 
4.18). Among tested ligands, only PGN slightly improved gene transcript levels. 
Contrary to results seen during adipogenic differentiation, addition of several other 
TLR ligands did not mediate any added effect during osteogenic differentiation 
process. Results revealed that PGN slightly improved alp, oc-1 and runx message 
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Osteo only Osteo + PGN Osteo only + p(I:C) 
Osteo only + R848 Osteo only + CpG Osteo only + C ODN 
Figure 4.17 - Osteocyte specific gene expressions for P0 MSCs 
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RNA expressions. The other ligands such as p(I:C), R848, and CpG ODN reduced 
expressions of these gene transcripts. Only, p(I:C) treated group has shown a 
decreased osteogenic profile.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The scenario of P0 rMSCs for the osteocyte differentiation is also applicable for P3 
rMSCs in the terms of osteocyte specific gene expression levels. Again in the p(I:C) 
treated group, the osteocyte specific gene expressions were decreased but the other 
groups showed no significant difference in the positive or negative direction 
compared to naïve group.    
 
4.3.2. RT-PCR Analysis of Toll-Like Receptor Panels 
 
We and others have demonstrated that MSCs do express TLRs (Pevsner-Fischer et al., 
2007; Schaffler et al., 2007) for TLR panels of specific rMSC passages see Section 
4.1.1.2.2.). Our previous observations also revealed that when immune cells were 
triggered by a specific TLR ligand, many TLRs do change their expression levels 
(Tincer, G., M.Sc. thesis). In an attempt to understand the variation of gene 
expression of different TLRs following ligand treatment was followed using cells 
undergoing adipogenic or osteogenic differentiations at P0 and P3 passages. Figures 
4.19 and 4.20 summarize the TLR panel obtained for P0 and P3 MSC undergoing 
adipogenic differentiation in the presence or absence of TLR ligand treatments. 
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Osteo only  Osteo + PGN  Osteo + p(I:C) 
Osteo + R848  Osteo + C ODN Osteo + CpG  
Figure 4.18 - Osteocyte specific gene expression panels of P3 rMSCs 
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Analysis of Figure 4.19, implicated that at P0 MSC undergoing in the presence of 
PGN upregulated TLR2, TLR6 and TLR9 gene transcripts more than adipose only 
medium group. Furthermore, CpG treatment upregulated its own receptor TLR9 
(Figure 4.19). At P0, other TLR ligands did not show any increase but significant 
reduction of the TLR gene expressions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This trend is quite the opposite when adipogenesis by P3 MSCs were analyzed. As 
seen in the Figure 4.20, adipocyte differentiation medium alone retained expression 
of TLR1, 3, 4, and 6, albeit at low levels. Addition of TLR2L (PGN), TLR3L 
(p(I:C)), TLR7L (R848) and TLR9L (CpG ODN) significantly boosted all of these 
TLRs.  The overview of TLR gene transcript variation is summarized in Table 4.4. 
Figure 4.19 - TLR panels of P0 rMSCs during adipogenic differentiation 
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Figure 4.20 - TLR panels of P3 rMSCs during adipogenic differentiation 
 56 
 
Table 4.4 - Effect of ligand treatment during P0 or P3 MSC differentiation in to adipocytes 
 
    * upregulated, * downregulated, * unchanged, UD undetected  
 
The effect TLR ligands on MSCs (at P0 and P3) undergoing osteogenesis were also 
analyzed by RT-PCR. Figures 4.21 and 4.22, as well as Table 4.5 provide gene 
expression profile analyses of these studies. 
 
As clearly seen in this set of data, addition of TLR ligands upregulated TLRs both in 
P0 and P3 (compare gel images of Figure 4.21 and 4.22) during osteogenesis.  
 
When taken together, upregulation of several TLRs throughout the course of 
differentiation has critical implications. Our findings strongly suggested that 
pluripotent MSCs when there is a microbial by product may become more strongly 
committed to undergo terminal differentiation possibly due to the inflammatory 
signals initiated by these ligands. These differentiated cells probably become more 
susceptible to triggering by the surrounding inflammatory signals (i.e. microbial by 
products present in that niche) and may lead to more robust immune modulatory 
responses. In order to further test this postulation additional experiments must be 
performed.  
 
 
MSC Rx TLR1 TLR2 TLR3 TLR4 TLR6 TLR7 TLR9
P0 Medium * ** **** ** ** UD * 
 PGN * *** ** ** ***  ** 
 p(I:C) UD * * * * UD  
 R848 UD * * * * UD  
 CpG UD * ** * * UD ** 
         
MSC Medium * UD ** * * UD UD 
P3 PGN ** * **** ** ** UD ** 
 p(I:C) ** UD **** ** ** UD ** 
 R848 * * *** ** ** UD ** 
 CpG ** * **** ** ** UD * 
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Figure 4.21 - TLR panels of P0 rMSCs during osteogenic differentiation 
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Figure 4.22 - TLR panels of P3 rMSCs during osteogenic differentiation 
 59 
 
Table 4.5 - Effect of ligand treatment during P0 or P3 MSC differentiation in to osteocyte 
 
 
     * upregulated, * downregulated, * unchanged, UD undetected 
 
4.4. Migration Assay 
 
Mesenchymal stem cells possess a very unique property known as “homing capacity” 
to the injured site. As described earlier, MSCs express TLRs, we reasoned that these 
TLRs may contribute to the “homing capacity” of the MSCs. In order to investigate 
this phenomenon, in vitro migration experiments were performed in the presence or 
absence of TLR ligands.   
 
As demonstrated in the Figure 4.23, migration capacity of mesenchymal stem cells 
significantly facilitated upon treatment with TLR ligands. In our hand, compared to 
media alone and control ODN groups, addition of TLR ligands improved the 
migration capacity more than 100% within 24 hours (Figure 4.23). This phenomenon 
is independent of the proliferative capacity induced by ligand stimulation, since our 
CFSE assay resulted insignificant proliferation among treatment groups (for more 
information please refer to Appendix C). 
 
 
 
MSC Rx TLR1 TLR2 TLR3 TLR4 TLR6 TLR7 TLR9
P0 Medium ** * **** *** ** UD * 
 PGN *** *** **** *** *** * *** 
 p(I:C) *** ** **** **** *** ** ** 
 R848 *** *** **** *** *** * *** 
 CpG *** *** **** *** *** UD *** 
         
MSC Medium ** * **** *** ** UD * 
P3 PGN ** ** ***** *** ** UD ** 
 p(I:C) ** * ***** *** ** UD * 
 R848 ** ** ***** **** **** UD ** 
 CpG ** ** ***** **** **** UD *** 
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Of note, the data presented here, along with TLR expression data (please see Table 
4.4 and 4.5 for details) strongly support the view of increased immunomodulatory 
capacity of MSCs due to TLR ligands induction. This implies that MSCs present in 
the microniche of tissues when exposed to microbial byproducts may be facilitated to 
terminally differentiate to organ specific cells. At the same time due to higher 
expression of TLRs they may become more immunomodulatory at that niche.  
 
4.5. Mouse Mesenchymal Stem Cells 
 
Although, in our laboratory substantial experience for rat mesenchymal stem cell 
generation was established, it was very challenging to conduct various assays due to 
limitations of the availability of rat specific consumables. However, historically 
considerable experience was accumulated in the lab utilizing mouse system. To 
further investigate whether MSCs initiate any immunomodulatory responses upon 
TLR ligand triggering we have decided to optimize mouse MSC generation from BM, 
and furthermore study these cells in the presence or absence of TLR stimulations. 
Lastly the interaction of MSCs with murine immune system cells in co-culture 
conditions. We assessed pro or inflammatory responses mediated by TLRs either 
from MSCs or their combination with splenocytes and determined cytokine secretion 
by ELISA. 
 
 
Figure 4.23 - Migration capacity of MSCs relative to MesenCult media and control group after 24 h
(* p<0.05, ** p<0.001, comparing to “Naïve group”). 
Migration percentage relative to naive group
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4.5.1. Characterization of Mouse Mesenchymal Stem Cell  
 
Since, cells types are same; they show nearly the same CD marker expression 
profiles and other mesenchymal stem cell properties. For instance, the isolation, 
generation and culturing of mouse MSCs are same as in rat mesenchymal stem cell 
system. Moreover, morphological structures and other physical properties are same 
for both mesenchymal stem cells. One difference which could be noticed by naked 
eye is the size between two cell types.  
 
 
 
 
 
 
 
 
 
 
Fibroblast-like mMSCs form colonies at the end of isolation procedure 
 
 
 
As seen in Figure 4.24, mMSCs are much smaller comparing to rMSCs. By the way, 
they have fibroblastic shape and form colonies as rMSCs did. 
 
4.5.1.1. PCR Results and Gel Images 
 
4.5.1.1.1. Toll-Like Receptor Expression Panels 
 
In order to generate mouse mesenchymal stem cells similar procedure conducted to 
generate MSCs from rat BM was applied. We further aimed to establish that these 
cells are indeed express TLRs. To pursue this we checked the presence of these 
genes by RT-PCR. One important difference between rMSCs and mMSCs is their 
successful passages. Consistent with the literature, it is very difficult to achieve 
Figure 4.24 - Microscopic appearance of mouse mesenchymal stem cells at the end of 14 days of 
isolation period (Mag = 10X) 
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several passages therefore, we only passaged them twice. In Figure 4.25, TLR 
expression profiles of P0 and P1 mMSCs are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From this data two points worth mentioning, i) mMSCs do not express TLR5 
(similar to rMSCs) but they do express substantial TLR7 transcript (contrary to 
rMSCs, please compare Figure 4.4 with Figure 4.25). Another discrepancy between 
rMSC is that here, TLR4 rather than TLR3 expressed at the highest level.  
 
4.6. Ability of mouse Mesenchymal Stem Cells to Secrete Cytokine following 
Toll-Like Receptor Ligand Stimulation  
 
After establishing that we can successfully generate mMSCs and these cells indeed 
expresses several TLRs we initiated immunostimulation assays and incubated cells 
with different TLR ligands (for the concentrations used please refer to Section 
3.2.3.3., Table 3.1). Initial experiments involved serial dilution of MSCs between 
2.5x102 to 5x105 cells. The aim of this experiment was to establish the optimum 
number of cells required to induce appreciable amount of cytokine secretion (Figure 
4.26). As seen here, maximum level of IL6 production was attained at 2.5x105 MSCs 
for all TLR ligands tested. Consistent with the PCR results, MSCs positive for TLR3, 
TLR4, TLR7 and TLR9 induced detectable and sufficient amounts of IL-6 
production at the end of 40 hours of incubation in culture. 
Figure 4.25 - TLR panels of P0 and P1 mMSCs 
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Another important point that should be mentioned is that A151 and Control ODN 
treated groups along with PGN (TLR2L) did not trigger any IL-6 release and 
behaved similar to the response seen for the untreated group. 
  
4.7. Co-culture Studies of mouse Mesenchymal Stem Cells with mouse 
Splenocytes  
 
Since the mesenchymal stem cells are regarded as “immunosuppressive”, and 
implicated that they are potentially suitable for the graft vs host disease applications, 
we planed to check their immunomodulatory performance when co-incubated with 
spleen cells in the presence or absence of TLR ligands at different cell ratios. In these 
experiments as a baseline positive controls MSC alone and splenocyte alone groups 
at two different cell concentrations were included. From the supernatants IL-6 and 
IFN production was studied with sandwich ELISA assay.  
 
As depicted in the Figure 4.27, contrary to expectations, from the IL-6 secretion 
levels there seems to be a synergy between spleen cells and MSCs when co-
incubated together at 1:1 ratio (please compare blue, yellow and grey bars of each 
treatment). When this ratio is not met, spleen cells are suppressing the MSC 
mediated IL-6 secretion. 
 
 
Figure 4.26 - IL-6 release results at different cell numbers for OD readings at 405 nm. (* p < 0.05,  
** p < 0.001, comparing to “Naïve group”, n=3). 
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There are few publications describing the immunomodulatory potential of MSCs 
when generated in culture. Although this topic was not thoroughly investigated by 
others, reports suggesting that MSCs might act as immunosuppressive cells are 
abundant to date. In our hand mouse BM generated MSC induced IL-6 in response to 
TLR ligand stimulation. Furthermore, these cells were potent IFNg producing cells 
when triggered by several TLR ligands. Their cytokine production ability was much 
superior than spleen cell culture (even when 5 fold more spleen cells were used).  
 
This observation has many important implications. One must be very cautious to 
consider using these cells in cases where immune suppressive effects by MSCs are 
desired.  
 
Another interesting point is that when MSCs and spleen cells were co-cultured, there 
was a strong synergistic effect in cytokine production. When the co-culture was 
treated with TLR ligand such as i) p(I:C), ii) R848, iii) CpG and iv) LPS the synergy 
in cytokine production was very significant. From the culture supernatants, parallel 
to IL-6 production, IFNg levels were also checked. Figure 4.28, demonstrates the 
outcome of this set of data.  
 
 
 
 
 
 
Figure 4.27 - IL-6 production profiles of MSC-Spleen cell co-culture at different ratio (* p < 0.01, 
 ** p < 0.001, comparing to “Naïve group”, n=3). 
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In this figure, results revealed that MSC only groups induced significantly high TLR 
mediated IFNg production (@P0). In the co-culture experiments, spleen cells 
reduced IFNg secretion levels produced by MSCs, and there is no synergy between 
these cells. On the contrary, there is a suppressive activity induced by spleen cells. 
Under the light of these findings, it is very complicated to dissect the interplay 
between MSCs and spleen cells. More detailed investigations are required in order to 
better describe the complex nature of this relation between MSC and other immune 
cells. One option is to co-culture purified B-, T-, Macrophage, dendritic cells with 
MSCs, and analyze the cytokine secretion characteristics of these mixed cells. May 
be then, one could describe which cells are synergizing with MSCs to increase 
cytokine production, or which cells are imposing suppressive effects to reduce the 
overall cytokine production. These and other related topics in the context of 
immunomodulation must be planned for the future studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28 - IFNg production profiles of MSC-Spleen cell co-culture at different ratio (* p < 0.05, 
** p < 0.01, comparing to “Naïve group”, n=3). 
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5.   DISCUSSION 
 
Mesenchymal stem cells (MSC) and the events initiated following stimulation with 
different TLR ligands was the main theme of this thesis. Throughout this project, the 
contribution of TLR mediated signaling on i) lineage specific MSC differentiation 
rate and efficiency, ii) migration and proliferative potential, and iii) changes in 
immunomodulatory activities regulated by MSCs were investigated. In our opinion, 
it was important to study these parameters, because in order to broaden the breath of 
the therapeutic applications of MSCs as well as to better understand the underlying 
biological phenomena regulated by TLR activation would help to impact the clinical 
utility of these versatile cell populations. 
 
In our study, characterization of mesenchymal stem cells was primarily pursued by 
checking CD90 expression as a positive marker and CD45 as a negative marker for 
rat MSC characterization. Along with these markers, CD106 was checked as a 
negative marker in rat system (Barzilay et al., 2009). At the end of 14 day isolation 
process, the immunophenotypic characterization revealed that the isolation process 
yielded impure population of rMSC. In order to reach homogeneous population, 
culturing of these cells over passages was performed. As a result the expression of 
CD90 rose from 30% to nearly 90% (Table 4.2) as expected CD45 and CD106 
expressions were negligible (ca. ~3-4%). This set of findings were in accordance 
with the reports in the literature (Harting et al., 2008). While FACS analysis of the 
cardinal surface markers at protein level was conclusive, due to the unavailability of 
several other critical markers we decided to analyze their gene expression patterns 
via PCR. 
 
In addition to surface marker analysis of mesenchymal stem cells by flow cytometry, 
the expressions of other negative and positive markers were checked at transcript 
level. Here, CD11b as a macrophage marker, and CD34 as a negative marker as well 
was included in the investigation. Moreover, other critical CD markers such as CD29, 
CD71, CD73, CD90, CD105 and CD166 were checked by PCR. According to these 
results, at P0 mesenchymal stem cells were still a heterogeneous population 
contaminated with other adherent/fibroblastoid cells. Separately, the cell population 
expressed CD73, CD105 and CD71. As expected, increasing the passage number 
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increased mesenchymal stem cells homogeneity. In P3, and in further passages, all 
negative CD marker transcripts were reduced to undetectable levels, where positive 
markers demonstrated an increase in gel band intensities. Although the transcript 
level analysis of CD markers reflects that we have a homogeneous population of 
related cell type, CD marker expressions should be further analyzed in the protein 
levels.   
 
Next, we investigated TLR expression profiles of BM generated MSCs. In our hand, 
rat MSCs expressed high levels of TLR1, 2, 3, 4, 6, and moderate levels of 7 and 9. 
Surprisingly, irrespective of passages, no TLR5 or TLR10 was detected. Since it is 
previously established that TLR8 was not present in rats, we did not check for the 
expression of this receptor. However, the expression levels of these receptors have 
decreased profoundly following culturing with one exception-TLR3. The reduction 
in the levels of several TLRs as opposed to increased passage number suggested that 
there was a significant reduction of the contaminating cells form P3 and onwards. It 
was previously reported that macrophages (Delneste et al., 2007) and hematopoietic 
stem cells (Kondo et al., 2003) were also expressing some TLRs. Thus, decrease in 
the TLR expression levels would not be surprising with the elimination of 
“contaminating” macrophages and hematopoietic stem cells. Yet, albeit at low levels 
TLR1, 2, 3, 4 and 6 expressions were retained until P12. Of note, among these TLRs 
TLR3 was expressed at very high levels at all passages. 
  
In this study, we have found that the TLR expression profile of mouse mesenchymal 
stem cells is different from previously reported (Pevsner-Fischer et al., 2007). We 
have consistently demonstrated that expression of TLR1, 2, 3, 4, 5, 6, 7, and 9 the 
present on mMSCs. One important note to point out is that, there is a distinct 
difference between rMSCs and mMSCs in terms of the pattern of TLR profiles.  
 
One of the main focus points of this thesis was to explore TLR contribution on the 
lineage-specific differentiation of MSCs. We established that different TLR ligands 
accelerated as well as increased adipogenic differentiation efficiency of rat 
mesenchymal stem cells at different several passages. On the contrary to our results, 
previously it was reported that TLR ligands especially PamCys3 (a TLR2 ligand), 
had a negative effect on the adipogenic differentiation of mesenchymal stem cells 
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(Pevsner-Fischer et al., 2007). However, in this study, a different ligand, 
peptidoglycan, for TLR2, was used in their work, instead of rat they used mouse 
MSCs.. The facilitating effects of TLR ligands on differentiation rates prompted us 
to terminate the incubation time significantly shorter than the normal differentiation 
process. This is a very significant finding, since conventional adipogenic 
differentiation procedure requires at least three weeks. This point is the most 
profound contribution of TLR ligands on MSC differentiation as it is the subject of 
this thesis. The accumulated data suggested that TLRL for TLR2, TLR3 and TLR7 is 
critical elements facilitating fast MSC to lineage–specific commitment. However, it 
is not possible to state that for each passage the contribution of TLR ligands were at 
the same level. For instance, in P3 CpG as TLR9 ligand has the highest contribution 
in adipogenic differentiation among the other TLR ligands while same ligand has a 
worse contribution trend in P0. A very highly possible reason for such results would 
be the contaminating cell populations present in P0 MSCs. These fluctuations would 
also be dependent on the TLR expression profiles of MSCs since there is a 
correlation between TLR expression levels and responsiveness of MSCs to these 
ligands (Liang et al., 2007). Another observation about the differentiation rates of 
treatment groups was that passaging resulted a decrease in the adipogenic 
differentiation capacity of MSCs. For instance, in P0 nearly hundred percent of cells 
have differentiated into adipocyte at the end of second week; whereas in P9, group 
with the highest adipocyte generation percentage exhibited only 25% conversion at 
the end of third week (compare Figs 4.8, vs 4.14). This observation was correlated 
with the literature. In recent studies, it was reported that passaging (no TLR 
involvement in these findings are associated) had a negative effect on the adipogenic 
differentiation capacity of MSCs (Wall et al., 2007; Yu et al., 2010). Our results 
advanced the existing literature information about the adipogenic differentiation of 
MSCs for several reasons, i) higher rates could be attained at a much lesser time and 
ii) conversion efficiencies are improved by the ligand supplementation to the 
differentiation media.  
 
It is inevitable that the most drastic effect of TLR ligands on MSC biology is the 
differentiation facilitating effects. This is a crucial question that why mesenchymal 
stem cells are differentiating faster into adipocyte when stimulated with TLR 
ligands? Here I would like to concentrate on the adipose tissue itself. Recently, 
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papers published in immunology journals are referring adipose tissue as an helper 
organ and part of the innate immune system (Schaffler et al., 2007). What’s more, in 
the inflammation status, expression of TLRs were shown to be increased in MSCs 
(Raicevic et al., 2010). Combining these two data, our results may build a bridge 
between these two interesting statements. Whenever mesenchymal stem cells are 
exposed to TLR ligands, here mimicking inflammation environment, these cells 
respond in the adipogenic differentiation direction, here generation of adipose tissue 
as an immunological organ. Such an observation and linkage is not present in current 
literature. Thus, our results stated here are the first to link adipogenic differentiation 
capacity of mesenchymal stem cells in an inflammation-like micro environment 
created with the use of TLR ligands.  
 
We have also analyzed the TLR expression profiles of different TLR ligand 
stimulated adipogenic and osteogenic differentiation groups. We have observed 
increases in the expression levels of specific TLRs in adipogenic and osteogenic 
differentiation groups (see Figure 4.24 and Figure 4.25). These results are again in 
concordance with the current literature (Liang et al., 2007; Raicevic et al., 2010).  
 
Apart from differentiation studies, we have also checked the effects of TLR ligands 
on the migration capacity of mesenchymal stem cells. Migration capacities of 
mesenchymal stem cells in the presence of  TLR ligands have increased as it was 
stated previously (Tomchuck et al., 2008). However, the migration capacities vary 
according to the TLR ligands stimulated with. The highest migrated group is p(I:C) 
which is TLR3 ligand and the least one is R848 which is TLR7 ligand. It is a hard 
question that what causes such a difference. Maybe the expression levels of related 
TLRs could be an answer to this question. Response levels to TLR ligands may 
correlate with the expression levels of related TLRs and as a result of this, migration 
capacities would exhibit such differences. All in all, migration capacities of 
mesenchymal stem cells have increased when stimulated with any TLR ligands. 
 
In mouse mesenchymal stem cell studies, immunosuppressive capacities of mMSCs 
were investigated. The experiment design was including co-culturing MSCs with 
splenocytes in the presence and/or absence of TLR ligands. Contrary to expected, our 
results have demonstrated a pro-inflammatory MSC type regardless of the splenocyte 
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presence. Actually these results are in coherent with the similar studies. TLR 
stimulation has gained MSCs an immunostimulatory phenotype in previous studies 
in terms of IL-6 secretion (Pevsner-Fischer et al., 2007; Romieu-Mourez et al., 2009). 
The most immunostimulatory phenotype of MSCs was observed in the R848, CpG 
and LPS treated groups; TLR7L, TLR9L and TLR4L, respectively in terms of both 
IL-6 and IFN-γ secretion. It is interesting that PGN treated group did not respond at 
same levels as other TLR ligands did for IFN-γ secretion. This may be due to the 
triggered signaling pathways of TLR2 ligand. Since PGN, as TLR2L, is a bacterial 
component, it is not surprising that this ligand did not stimulate the anti-viral 
cytokine, IFN-γ, secretion. Besides these results, A151 as an immunosuppressive 
ODN has successfully inhibited the secretion of both IL-6 and IFN-γ cytokines in all 
groups. This inhibition is also a significant result in terms of immunosuppresion.  
 
Since mesenchymal stem cells were said to be immunosuppressive, the presence of 
potential subpopulations is also a possibility and stands as an important issue in the 
way of MSC biology. As in our case, a potential pro-inflammatory phenotype of 
MSC would give such unexpected results. Surprising results of co-culturing 
experiments would be due to a MSC subpopulation with pro-inflammatory 
phenotype. 
 
In conclusion, this thesis study clearly demonstrates that TLR ligands have 
significant effects on mesenchymal stem cell biology in terms of adipogenic 
differentiation, migration and stimulation of the immune system. Moreover, a 
potential subpopulation of MSC with immunostimulatory character is present and it 
is essential to isolate such subpopulations of MSCs for proper and reliable 
administration of these cells.  
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6. FUTURE PERSPECTIVES 
 
This study has stated the TLR contribution to adipogenesis of rat mesenchymal stem 
cells and enhancement in the migration capacity of these cells. Moreover, the 
immunomodulatory effects of these cells in the presence and/or absence of TLR 
ligands were revealed out.  
 
Unfortunately, the first thing to handle with MSC studies should be the 
standardization of the characterization issue of these cells. For our laboratory, more 
surface markers, both positive and negative ones, should be checked with proper 
controls. On the other side, differentiation protocols other than adipogenesis, like 
osteogenesis and chondrogenesis, should be established. With such differentiation 
protocols, it would be more reliable to introduce these cells as mesenchymal stem 
cells.  
 
Even though the results mentioned here are striking, a similar study to this one 
should be carried out in other systems like mice. If the same trend should be seen in 
another system, without doubt it is possible to say that TLRs facilitate the 
differentiation process of mesenchymal stem cells. As previously stated in MSC 
niches section, there are several tissues for MSC residing. Other studies may be 
carried out with MSCs isolated from these tissues. It is highly possible that some 
kind of differences would be observed with these tissues. In addition to such studies, 
other differentiation processes should be investigated under TLR stimulations.  
 
About the most dramatic findings of this study, the fundamental molecular 
mechanisms of adipogenesis should be deeply studied in order to delineate at which 
state, TLRs contribute to this process. For this reason, the underlying mechanisms of 
adipogenesis should be studied along with immune system since adipose tissue is 
“called” as an immune system organ (Schaffler et al., 2006). May be, it would be 
significant to study the mesenchymal stem cells of obese vs healthy mice in terms of 
TLR expression and adipogenic differentiation capacity.  
 
The migration of mesenchymal stem cells is also a significant issue to study. The 
migration pace of these stem cells was increased when they were stimulated with 
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TLR ligands. Just like a previous study, migration capacity should be investigated in 
an in vivo system (Kocak et al, 2010, submitted to J Hepatol). However, this time 
TLR ligand pre-treated MSCs should be administered to the animal with a wound 
model. After proper time points, animals should be sacrificed and the wounded organ 
should be deeply studied for MSC localization differences in cell number. Such a 
study would be much more valuable in terms of deciphering TLR ligand effects on 
migration capacity of MSCs. 
 
Another concept which should be further studied is the subpopulation 
characterization of these stem cells. If there are really two types of MSC populations 
according to their immunomodulatory phenotype, dissecting these two groups would 
have profound effect in terms of suitable MSC choose in therapeutic applications. 
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8. APPENDICES 
8.1. Appendix A  
 
Standard Solutions, Buffers, and Culture Media.  
 
Blocking Buffer (ELISA)  
 
• 500 ml 1x PBS  
• 25 grams BSA (5%)  
• 250 μl Tween20 (0,025%)  
 
Store at -20°C. 
 
T-cell Buffer [ELISA]  
 
• 500 ml 1x PBS  
• 25 ml FBS (5%)  
• 250 μl Tween20 (0,025%)  
 
Store at -20°C. 
 
Wash Buffer [ELISA]  
 
• 500 ml 10x PBS  
• 2,5 ml Tween20  
• 4,5 lt ddH2O  
 
Prepare prior to usage and use immediately.  
 
Loading Dye  
 
• 0,009 grams Bromofenol blue  
• 0,009 grams Xylen cyanol  
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• 2,8 ml ddH2O  
• 1,2 ml 0,5M EDTA  
• 11 ml glycerol  
 
PBS (Phosphate Buffered Saline) [10X]  
 
• 80 grams NaCl  
• 2 grams KCl  
• 8,01 grams Na2HPO4 . 2H2O  
• 2 grams KH2PO4  
 
Complete into 1 lt with ddH2O. Adjust to pH=6,8 with HCl. For 1X PBS, pH 
should be ≈ 7,2-7,4. After adjustment of pH, autoclave.  
  
TAE (Tris-Acetate-EDTA) [50X]  
 
• 242 grams Tris (C4H11NO3)  
• 37,2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2.2H2O)  
• 57,1 ml Glacial acetic acid  
 
Complete to 1 lt final volume with ddH2O. Autoclave and dilute to 1X prior to 
use.  
 
PBS-BSA-Na azide  
 
• 500 ml 1x PBS  
• 5g BSA (1%)  
• 125mg  Na-Azide (0,25%)  
 
RPMI-1640 (Hyclone)  
 
• 5 % : 25 ml FBS (Oligo FBS = inactivated at 65°C, Regular FBS = inactivated 
at 55°C )  
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• 5 ml Penicillin/Streptomycin (50 μg/ml final concentration from 10 mg/ml 
stock)  
• 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M 
stock )  
• 5 ml Na Pyruvate, (0,11 mg/ml final concentration from 100mM, 11 mg/ml 
stock)  
• 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x 
concentrate stock)  
• 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock)  
 
Prepare in 500 ml media. 
 
MesenCult® (STEMCELL Technologies, Canada) 
 
• 400 ml MesenCult® Basal Medium for Mouse Mesenchymal Stem Cells 
• 100 ml MesenCult® Mesenchymal Stem Cell Stimulatory Supplements 
• 5 ml Penicillin/Streptomycin (50 μg/ml final concentration from 10 mg/ml 
stock).  
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8.2. Appendix B-1 
Figure 8.1 - CD marker expression panels over passages for characterization 
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Figure 8.2 - TLR expression panels over rMSC passages 
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8.3. Appendix B-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
>TLR9L = CpG  TLR2L = PGN Adipogenic medium only >
TLR3L = p(I:C) TLR7L = R848 Control ODN > >
Figure 8.3 - Photomicrographs of rMSC (@P3) differentiated to adipocytes at D5 (Mag = 20X) 
> > Adipogenic medium only  TLR3L = p(I:C) Control ODN 
TLR7L = R848 TLR9L = CpG  TLR2L = PGN 
Figure 8.4 - Photomicrographs of rMSC (@P3) differentiated to adipocytes at D11 (Mag = 20X) 
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Adipogenic medium only  TLR3L = p(I:C) TLR9L = CpG  > > 
> Control ODN TLR2L = PGN TLR7L = R848 > 
Figure 8.5 – Photomicrographs of rMSC (@P6) differentiated to adipocytes at D5 (Mag = 20X) 
> >Control ODN TLR2L = PGN TLR7L = R848 
> > Adipogenic medium only  TLR9L = CpG  TLR3L = p(I:C) 
Figure 8.6 – Photomicrographs of rMSC (@P6) differentiated to adipocytes at D8 (Mag = 20X) 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
> => TLR2L = PGN TLR3L = p(I:C) TLR7L = R848 
Adipogenic medium only Control ODN TLR9L = CpG  > > 
Figure 8.7 – Photomicrographs of rMSC (@P6) differentiated to adipocytes at D10 (Mag = 20X) 
Adipogenic medium only  TLR3L = p(I:C) TLR7L = R848 
TLR2L = PGN Control ODN TRL9L = CpG  
Figure 8.8 – Photomicrographs of rMSC (@P9) differentiated to adipocytes at the end 1st week  
(Mag = 20X) 
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> > Adipogenic medium only Control ODN TLR3L = p(I:C) 
> > TLR9L = CpG  TLR2L = PGN TLR7L = R848 
Figure 8.9 - Photomicrographs of rMSC (@P9) differentiated to adipocytes at the end of 2nd week 
(Mag = 20X) 
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8.4. Appendix C 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.1 - MSC proliferation rates after TLR ligand treatment expressing proliferation assessed by 
CFSE assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment groups MFI analysis results (%) 
MesenCult only 39.86 
TLR2L = PGN 35.14 
TLR3L = p(I:C) 31.91 
TLR7L = R848 40.90 
TLR9 = CpG 33.62 
Control ODN 37.02 
Figure 8.10 - Representative histograms and analysis of proliferation rate by CFSE assay. A) Naïve 
and B) p(I:C) treated MSCs 
B A 
